One-year period ending June 30, 2023. Click on a title to read more.
Awards information as defined in UW SAGE.
| Title | Principal Investigator (PI) | Department | Sponsor | Amount | Research Award Date | Abstract | Personnel | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A181435 | FA218511 | 66-9179 | 2021 | PFIZER 2022 | Fragmentation-Based Characterization of CYP3A4 Adducts | New | Research: Basic | Contract | 864002247 | TOTAH, RHEEM A. | 3080003000 | MEDICINAL CHEMISTRY | SCHOOL OF PHARMACY | Pfizer, Inc. | Private Industry | No | Pfizer, Inc. | $225,474 | Returned by GCA | 55.5 | 2/1/2023 | 8/31/2023 | 2/8/2023 | 2023 | A181435 | Associate Professor | Due to its prominence in drug metabolism, cytochrome P450 (CYP) mediated drug-drug interactions (DDIs) are of primary concern. However, the ability to predict accurately the magnitude of clinical DDIs resulting from time-dependent inactivation (TDI) of CYPs based on in vitro parameters is generally poor. Therefore, significant efforts on the part of both medicinal chemists and drug metabolism scientists are generally undertaken to design out or minimize CYP inactivation. Currently employed approaches are limited to empirical screening of analogs in high/moderate throughput CYP inactivation assays with the aim of identifying analogs with reduced or insignificant inactivation potential. Such tactics are labor intensive, often unsuccessful, and provide only kinetic data for inactivation. Failures to eliminate CYP inactivation can, in part, be explained by an incomplete understanding of the mechanistic underpinnings of CYP inactivation. We propose to fund a post-doctoral fellow in the laboratory of Rheem Totah at the University of Washington. The focus of the work of this post-doc will be to establish mechanistic and structural understanding of CYP time-dependent inactivation (TDI) via mass spectrometric (MS) analyses of intact protein and proteolytic peptides. Identified drug-protein adducts will provide medicinal chemists actionable data regarding the inactivation mechanism and may provide avenues to enable more rapid implementation of avoidance strategies for TDI. The specific aims of this proposal are to develop MS assays for identification and characterization of CYP proteins adducted by small molecules and to provide additional structural data as to the nature of the small molecule adducts. | Totah, Rheem A., Principal Investigator, Associate Professor, MEDICINAL CHEMISTRY • Kanov, Jeanine M., Administrative Contact, ADMINISTRATOR, Department of Medicinal Chemistry, MEDICINAL CHEMISTRY • Lidzbarski, Erik August Lee, Budget Contact, BUDGET/FISCAL ANALYST, MedChem - Admin, MEDICINAL CHEMISTRY • Kanov, Jeanine M., eGC1 Preparer, ADMINISTRATOR, Department of Medicinal Chemistry, MEDICINAL CHEMISTRY |
|
| A171542 | FA222966 | 62-5515 | 2021 | NEXTGEN PEDS | NextGen Targeted and Long-acting Combination ART for Children with HIV | Non-Competing Revision | Research: Basic | Grant | 867006435 | HO, RODNEY J.Y. | 3080004000 | PHARMACEUTICS | SCHOOL OF PHARMACY | National Institute of Allergy and Infectious Diseases (NIAID) | DHHS-National Institutes of Health (NIH) | Yes | National Institute of Allergy and Infectious Diseases (NIAID) | $1,424,502 | 5R33AI149665-04 | Processed | 55.5 | 4/18/2022 | 3/31/2025 | 3/17/2023 | 2023 | A171542 | Professor | The Targeted, Long-acting and Combination Anti-Retroviral Therapeutic (TLC-ART) Program has developed a scalable, drug-combination nano-platform technology called DcNP that enables the stabilizing of insoluble and soluble HIV drugs together in an injectable suspension intended for children. The proposed transition plan is intended to select a lead and back up drug-combination candidate to support clinical development of a long-acting HIV treatment product for children. In the past 1.5 year, the team has made significant progress that we believe met or exceed the milestones laid out in the original award agreement. This transitional review package is assembled for a formal review and request for proceeding the proposed R33 phase award. | Ho, Rodney J.Y., Principal Investigator, Professor, PHARMACEUTICS • Jonsson, Christine Anne, Other, MANAGER OF PROGRAM OPERATIONS, Department of Medic, DEPARTMENT OF MEDICINE • Collier, Ann C, Co-Investigator, Professor without Tenure, DEPARTMENT OF MEDICINE • Beima-Sofie, Kristin M, Co-Investigator, Acting Assistant Professor, GLOBAL HEALTH • Jonsson, Christine Anne, Administrative Contact, MANAGER OF PROGRAM OPERATIONS, Department of Medic, DEPARTMENT OF MEDICINE • Jonsson, Christine Anne, Budget Contact, MANAGER OF PROGRAM OPERATIONS, Department of Medic, DEPARTMENT OF MEDICINE • Fukuda, Yuichi, eGC1 Preparer, Program Operations Specialist (E S 7), DEPARTMENT OF MEDICINE • Fukuda, Yuichi, Advance Preparer, Program Operations Specialist (E S 7), DEPARTMENT OF MEDICINE |
| A179263 | FA214958 | 62-7048 | 2021 | K01 JING LI | Effect of Medicare Reimbursement for Care Planning on End of Life Care among Patients with Alzheimer's Disease and Related Dementias: A Quasi-Experimental Study | Transfer from Another Institution | Research: Applied | Grant | 815006520 | Li, Jing | 3080001000 | DEPARTMENT OF PHARMACY | SCHOOL OF PHARMACY | National Institute on Aging (NIA) | DHHS-National Institutes of Health (NIH) | Yes | National Institute on Aging (NIA) | $116,006 | 7 K01 AG 066946-04 | Processed | 8.0 | 1/15/2023 | 5/31/2025 | 1/31/2023 | 2023 | A179263 | Assistant Professor | Deaths of older adults with Alzheimer's disease and Alzheimer's Disease-related dementias (AD/ADRD) are common and fast growing, while end-of-life care for AD/ADRD patients is often overly aggressive and costly. Advance care planning (ACP), the discussion of patient preferences and goals of care in the event of patient losing decision-making capacity, holds promise in curbing overly aggressive EOL care for AD/ADRD patients. This project aims to evaluate the effect of two recent Medicare reimbursement policy changes that promote ACP practice, providing rigorous and critical evidence for improving EOL care among AD/ADRD patients. | Li, Jing, Principal Investigator, Assistant Professor, DEPARTMENT OF PHARMACY • Basu, Anirban, Key Personnel, Professor, DEPARTMENT OF PHARMACY • Kimura, Maya, Administrative Contact, ADMINISTRATOR, Department of Pharmacy, DEPARTMENT OF PHARMACY • Ahmed, Saveena, Budget Contact, Program Operations Analyst (E S 7), DEPARTMENT OF PHARMACY • Camp, Alyssa L, eGC1 Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY • Camp, Alyssa L, Budget Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY • Camp, Alyssa L, Advance Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY |
| A179669 | FA222768 | 62-8870 | 2021 | DRUG COMBO NANO RESUB | Drug combination nanoparticles for advanced treatment of metastatic TNBC | Resubmission (Previously Denied) | Research: Applied | Grant | 850004461 | Mu, Qingxin | 3080004000 | PHARMACEUTICS | SCHOOL OF PHARMACY | National Institutes of Health (NIH) | DHHS-National Institutes of Health (NIH) | Yes | National Institutes of Health (NIH) | $199,842 | 1 R21 CA 273739-01A1 | Processed | 55.5 | 3/10/2023 | 2/28/2025 | 3/17/2023 | 2023 | A179669 | Acting Assistant Professor | Triple negative breast cancer (TNBC) is the most challenging subtype to treat among all breast cancer cases due to lack of cell surface receptors. Patients with metastatic TNBC have median overall survival of only 13.3 months with treatment. Newly approved immune checkpoint inhibitors such as PD-1 antibody only extend the survival by 2-4 months when used with chemotherapy, and the efficacy highly relies on expression of targets such as PD-L1 in tumors. Despite new treatment options, metastatic TNBC is predominantly treated by highly potent chemotherapy, with combination therapy being advantageous over single agents regarding response rate and overall survival. However, the drugs in combination chemotherapy have distinct physicochemical properties that hinders formulation into single dosage; their distinct pharmacokinetic behavior hinders the in vivo synergism. Furthermore, these drugs are non-specific to cancer cells and often show systemic toxicity. Our long-term goal is to develop advanced and well-characterized drug delivery approaches to improve treatment outcomes of drugs and drug combinations. In this project, we propose a dual-drug loaded dual-peptide ligand incorporated drug combination nanoparticle (DCNP) approach for targeting and inhibition of metastatic TNBC. The lipid-based DCNP leverage on effective gemcitabine and paclitaxel combination in clinic to deliver both drugs in prolonged and synchronized manner. Through incorporation of two peptide ligands that targets TNBC cells (through ICAM-1) and tumor vasculature (through endoglin), the DCNP could target both primary tumor and metastasis for enhanced chemotherapy. Furthermore, both drugs are reported to upregulate PD-L1 and reduce population of myeloid derived suppressor cells (MDSCs) in the tumor. These effects can sensitize TNBC cells for PD-1/PD-L1 therapy. The DCNPs that synchronize and co-deliver both drugs may further augment such effects thus generate improved chemoimmuno therapeutic outcomes. The objectives of this project are to validate the concepts of improved targeting and chemotherapy of metastatic TNBC with a dual-targeting DCNP approach and enhanced combination therapy with immune checkpoint inhibitors. In Aim 1, we will prepare ligands-incorporated DCNPs with high drug loading, proper size, and good stability, and test their cellular binding and efficacy, and effects on cancer cell expression of PD-L1. In Aim 2, we will validate enhanced in vivo targeting efficiency with the dual-ligand strategy and correlate it with expression levels of receptors and evaluate inhibition of primary tumor and metastasis with monitoring of survival. In Aim 3, we will assess the upregulation of PD-L1 and reduction of MDSCs by the DCNPs and carry out a pilot survival study with a chemoimmuno combination regimen. If successful, this targeted drug combination strategy could substantially improve the treatment of metastatic TNBC. Through tuning composition and targeting ligands, this highly translatable nanoformulation technology can be potentially used for existing and future drug combinations to treat various metastatic cancers. | Mu, Qingxin, Principal Investigator, Acting Assistant Professor, PHARMACEUTICS • Disis, Mary L., Key Personnel, Professor without Tenure, DEPARTMENT OF MEDICINE • Ho, Rodney J.Y., Co-Investigator, Professor, PHARMACEUTICS • Ferrari, Mauro, Co-Investigator, Affiliate Professor, PHARMACEUTICS • Kirkpatrick, Leila, Administrative Contact, Grants And Contracts Manager/Specialist (E S 8), PHARMACEUTICS • Kirkpatrick, Leila, Budget Contact, Grants And Contracts Manager/Specialist (E S 8), PHARMACEUTICS • Kirkpatrick, Leila, eGC1 Preparer, Grants And Contracts Manager/Specialist (E S 8), PHARMACEUTICS • Kirkpatrick, Leila, Budget Preparer, Grants And Contracts Manager/Specialist (E S 8), PHARMACEUTICS • Kirkpatrick, Leila, Advance Preparer, Grants And Contracts Manager/Specialist (E S 8), PHARMACEUTICS |
| A183778 | FA218091 | 66-7468 | 2021 | DUKE PK COMMON DRUG | PK and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants | New | Clinical Trial: Federal Sponsors | Contract | 871002110 | Hebert, Mary F | 3080001000 | DEPARTMENT OF PHARMACY | SCHOOL OF PHARMACY | Duke University | Private School, College, University | No | National Institutes of Health (NIH) | $293,000 | 8308 BMS01 | Processed | 55.5 | 9/23/2021 | 9/22/2024 | 3/20/2023 | 2023 | A183778 | Professor | This clinical trial agreement will consist of of individual protocols to study the PK and safety of commonly used drugs in lactating women and breastfed infants. | Hebert, Mary F, Principal Investigator, Professor, DEPARTMENT OF PHARMACY • Kimura, Maya, Administrative Contact, ADMINISTRATOR, Department of Pharmacy, DEPARTMENT OF PHARMACY • Ahmed, Saveena, Budget Contact, Program Operations Analyst (E S 7), DEPARTMENT OF PHARMACY • Camp, Alyssa L, eGC1 Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY • Camp, Alyssa L, Advance Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY |
| A180949 | FA215012 | 66-8206 | 2023 | UCB PHI MATCH | Community Pharmacist Epilepsy Services Program | New | Other Sponsored Activity | Contract | 848005505 | Bacci, Jennifer Lynn | 3080001000 | DEPARTMENT OF PHARMACY | SCHOOL OF PHARMACY | UCB, Inc. | Private Industry | No | UCB, Inc. | $231,784 | PO 4300111254 | Processed | 37.0 | 10/7/2022 | 1/31/2024 | 1/23/2023 | 2023 | A180949 | Associate Professor | The overall goal of this proposed Tier 3 study seeks to pilot the community pharmacist population health intervention for PWE in community pharmacies in Washington State. The research team will pursue the following aims: (1) develop a training program and evaluate its impact on community pharmacists’ ability to provide the community pharmacist population health intervention and (2) evaluate the impact of the community pharmacist population health intervention on PWE’s QoL and health outcomes. This study will advance our efforts towards the long-term goal of scaling an effective intervention to improve the humanistic, clinical, and economic outcomes for PWE. | Bacci, Jennifer Lynn, Principal Investigator, Associate Professor, DEPARTMENT OF PHARMACY • White, Harold Steve, Key Personnel, Professor, DEPARTMENT OF PHARMACY • Stergachis, Andreas S, Key Personnel, Professor, DEPARTMENT OF PHARMACY • Guignet, Michelle, Key Personnel, Postdoctoral Scholar (E S UAW Postdoc), DEPARTMENT OF PHARMACY • ZARAA, SABRA, Other, Graduate Research Student Assistant (NE H UAW ASE), DEPARTMENT OF PHARMACY • Kimura, Maya, Administrative Contact, ADMINISTRATOR, Department of Pharmacy, DEPARTMENT OF PHARMACY • Camp, Alyssa L, Budget Contact, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY • Camp, Alyssa L, eGC1 Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY • Camp, Alyssa L, Budget Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY • Camp, Alyssa L, Advance Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY |
| A187296 | FA220679 | 66-8953 | 2021 | PATH GHANA 2023 | Utilizing Private Pharmacy Capacity and Systems for COVID-19 Vaccine Delivery and Future Life-Course Vaccines | New | Research: Applied | Grant | 874005710 | Stergachis, Andreas S | 3080001000 | DEPARTMENT OF PHARMACY | SCHOOL OF PHARMACY | PATH | Association & Non-Profits | No | PATH | $30,000 | Catalyst.1104674-01720170-SUB | Processed | 55.5 | 1/5/2023 | 4/30/2023 | 2/9/2023 | 2023 | A187296 | Professor | Under the oversight of Dr. Stergachis, University of Washington study personnel will continue activities for the PATH/Ghana Pharmacy T.R.U.S.T. Initiative, aiming to train pharmacists in Ghana to safely administer life-course vaccines. The UW study team will continue to engage in collaborative efforts with PATH, Ghana College of Pharmacy, and Ghana Ministry of Health on finalizing the pharmacists as vaccinators training program, advising on the hands-on practical training of pharmacists and the curriculum for pharmacy schools in Ghana, and participate in analyses and dissemination activities, including collaborative publications. | Stergachis, Andreas S, Principal Investigator, +AD8Professor, DEPARTMENT OF PHARMACY • Sullivan, Catrena J, Other, Unpaid Academic, DEPARTMENT OF PHARMACY • Kimura, Maya, Administrative Contact, ADMINISTRATOR, Department of Pharmacy, DEPARTMENT OF PHARMACY • Ahmed, Saveena, Budget Contact, Program Operations Analyst (E S 7), DEPARTMENT OF PHARMACY • Camp, Alyssa L, eGC1 Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY • Camp, Alyssa L, Budget Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY • Camp, Alyssa L, Advance Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY |
| A187972 | FA221544 | 66-9336 | 2021 | BEAT MS 2022-2023 | Beat MS | Non-Competing Renewal | Clinical Trial: Federal Sponsors | Grant | 863005316 | CARLSON, JOSHUA J. | 3080001000 | DEPARTMENT OF PHARMACY | SCHOOL OF PHARMACY | Benaroya Research Institute at Virginia Mason | Association & Non-Profits | No | National Institute of Allergy and Infectious Diseases (NIAID) | $43,310 | FY23ITN293 AM4 | Processed | 55.5 | 2/1/2023 | 1/31/2024 | 2/17/2023 | 2023 | A187972 | Associate Professor | Dr. Carlson, will perform an economic analysis alongside of the clinical trial, BEAT-MS. Specifically, he will be responsible for the study design, data analysis, and interpretation of data for the within trial economic analyses and the development, analysis and interpretation of the simulation model for the long-term economic analysis. He will participate the development of the protocol, study materials, and data collection forms related to the CEA. He will advise on all project aims from the health economics perspective. | Carlson, Joshua J., Principal Investigator, Associate Professor, DEPARTMENT OF PHARMACY • Kimura, Maya, Administrative Contact, ADMINISTRATOR, Department of Pharmacy, DEPARTMENT OF PHARMACY • Ahmed, Saveena, Budget Contact, Program Operations Analyst (E S 7), DEPARTMENT OF PHARMACY • Camp, Alyssa L, eGC1 Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY • Camp, Alyssa L, Budget Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY |
| A176252 | FA222591 | 66-9840 | 2021 | SUNY SUB | Cholesterol homeostasis in the vertebrate retina | New | Research: Basic | Grant | 849005600 | XU, LIBIN | 3080003000 | MEDICINAL CHEMISTRY | SCHOOL OF PHARMACY | State University of New York (SUNY), Buffalo | Public School, College, University | No | National Institutes of Health (NIH) | $34,101 | R1343633 | Processed | 55.5 | 3/1/2023 | 2/29/2024 | 3/16/2023 | 2023 | A176252 | Associate Professor | Our current understanding of cholesterol (Chol) homeostasis in the retina remains rudimentary. Hereditary defects in Chol biosynthesis comprise a family of severe, often lethal, metabolic disorders. Smith-Lemli-Opitz Syndrome (SLOS) was the first such disease discovered. SLOS involves defective conversion of 7-dehydrocholesterol (7DHC) to Chol, which is catalyzed by DHCR7 (7-dehydrocholesterol reductase). Here, we will generate novel, genetically-modified mouse models of SLOS, targeting ablation of the Dhcr7 gene in selective cell types and tissues. We hypothesize that PRs rely heavily upon uptake of Chol from RPE cells, M?ller glia, and blood-borne lipoproteins to meet their sterol demands. We will test our hypothesis via the following Aims. In Aim 1, we will selectively knock out Dhcr7 in rod PRs and, separately, in Müller glia and then assess the impact on retinal structure, function, and sterol composition. In Aim 2, we will selectively knock out Dhcr7 in RPE cells and, separately, in hepatocytes and then assess the impact on retinal structure and function and sterol composition. In Aim 3, we will use normal human and SLOS patient iPSC-derived RPE cells (now in-hand), as well as a novel, tandem-tagged autophagy reporter mouse model, to elucidate the mechanism by which disrupted Chol biosynthesis in RPE cells leads to defective autophagy/heterophagy. In Aim 4, we will utilize hepatocyte-specific Dhcr7 knockout mice vs. wildtype mice to assess sterol efflux rates from the neural retina. The results obtained will provide new insights into mechanisms underlying retinal pathology associated with Chol synthesis defects, potentially leading to more effective therapeutic interventions for SLOS and related orphan diseases. The Xu Lab at UW will carry out analysis of sterols and oxysterols proposed in this project. | Xu, Libin, Principal Investigator, Associate Professor, MEDICINAL CHEMISTRY • Zhang, Rutan, Other, Postdoctoral Scholar, MEDICINAL CHEMISTRY • Kanov, Jeanine M., Administrative Contact, ADMINISTRATOR, Department of Medicinal Chemistry, MEDICINAL CHEMISTRY • Lidzbarski, Erik August Lee, Budget Contact, BUDGET/FISCAL ANALYST, MedChem - Admin, MEDICINAL CHEMISTRY • Kanov, Jeanine M., eGC1 Preparer, ADMINISTRATOR, Department of Medicinal Chemistry, MEDICINAL CHEMISTRY • Kanov, Jeanine M., Budget Preparer, ADMINISTRATOR, Department of Medicinal Chemistry, MEDICINAL CHEMISTRY |
| A181637 | FA222959 | 66-9848 | 2021 | ADA IBSPM | Control of energy and glucose homeostasis by hypothalamic perineuronal nets | New | Research: Basic | Grant | 845005768 | ALONGE, KIMBERLY M. | 3080003000 | MEDICINAL CHEMISTRY | SCHOOL OF PHARMACY | American Diabetes Association (ADA) | Association & Non-Profits | No | American Diabetes Association (ADA) | $115,000 | 11-22-IBSPM-06 | Processed | 10.0 | 11/15/2022 | 11/14/2023 | 3/16/2023 | 2023 | A181637 | Acting Assistant Professor | The brain plays a key role to control food intake, body fat mass, and blood glucose levels. and defective nutrient and hormone sensing in the arcuate nucleus (Arc) of the mediobasal hypothalamus (MBH) is implicated in the pathogenesis of obesity and type 2 diabetes (T2D). Recent evidence suggests that obesity impairs responsiveness of hypothalamic metabolite-sensing neurons involved in energy and glucose homeostasis, although mechanisms underlying these defects are unknown. Mechanism governing neuron activity in other sensory input regions of the brain involves extracellular matrix structures, termed perineuronal nets (PNNs), which surround sensory neurons and act to bind proteins and other factors and facilitate their interaction with the enmeshed neuron. Recently, the presence of these unique PNNs have been identified surrounding metabolite-sensing neurons in the hypothalamic of normal mice, rats, and humans, and moreover, that both PNN abundance and composition are abnormal in rat models of T2D. These results imply a possible link between changes in Arc PNNs and impairment in regulating energy and glucose metabolic homeostasis underlying metabolic diseases. Considering the loss of PNNs in rat models of T2D, the overall hypothesis states that changes Arc PNN extracellular matrices associate with obesity, T2D, and other associated metabolic derangements in humans. Basic and translational studies proposed within this ADA Innovative Basic Science award mechanism seek to 1) clarify the role of PNNs in nutrient and hormone signaling in the hypothalamus of rats, and 2) determine whether findings of altered PNN abundance and composition in rats are observed in normal, obese, and T2D humans. | Alonge, Kimberly M., Principal Investigator, Acting Assistant Professor, DEPARTMENT OF MEDICINE • Phan, Bao Anh N, Other, Research Scientist/Engineer 2 (E S 7), DEPARTMENT OF MEDICINE • Kanov, Jeanine M., Administrative Contact, ADMINISTRATOR, Department of Medicinal Chemistry, MEDICINAL CHEMISTRY • Lidzbarski, Erik August Lee, Budget Contact, BUDGET/FISCAL ANALYST, MedChem - Admin, MEDICINAL CHEMISTRY • Kanov, Jeanine M., eGC1 Preparer, ADMINISTRATOR, Department of Medicinal Chemistry, MEDICINAL CHEMISTRY • Kanov, Jeanine M., Budget Preparer, ADMINISTRATOR, Department of Medicinal Chemistry, MEDICINAL CHEMISTRY |
| A181223 | FA218453 | 80-1148 | 2021 | BAYER FLWSHP 2023-24 | Bayer Fellowship Program | New | Fellowship: Research Graduate/Professional | Contract | 861003065 | HANSEN, RYAN | 3080001000 | DEPARTMENT OF PHARMACY | SCHOOL OF PHARMACY | Bayer HealthCare Pharmaceuticals, Inc. | Private Industry | No | Bayer HealthCare Pharmaceuticals, Inc. | $258,447 | US208322059710P | Processed | 9.0 | 7/25/2022 | 12/31/2025 | 3/3/2023 | 2023 | A181223 | Associate Professor | Bayer will support a two-year fellowship program in Health Economics and Outcomes Research (HEOR) through the University and its Department of Pharmacy. | Hansen, Ryan, Principal Investigator, Associate Professor, DEPARTMENT OF PHARMACY • Carlson, Joshua J., Other, Professor, DEPARTMENT OF PHARMACY • Basu, Anirban, Other, Professor, DEPARTMENT OF PHARMACY • Sullivan, Sean, Other, Professor, DEPARTMENT OF PHARMACY • Veenstra, David, Other, Professor, DEPARTMENT OF PHARMACY • Devine, Emily E., Other, Professor, DEPARTMENT OF PHARMACY • Bansal, Aasthaa, Other, Associate Professor, DEPARTMENT OF PHARMACY • Barthold, Douglas G., Other, Research Assistant Professor, DEPARTMENT OF PHARMACY • Marcum, Zachary, Other, Associate Professor, DEPARTMENT OF PHARMACY • Bacci, Jennifer Lynn, Other, Associate Professor, DEPARTMENT OF PHARMACY • Ramsey, Scott D., Other, Professor without Tenure, DEPARTMENT OF MEDICINE • Kimura, Maya, Administrative Contact, ADMINISTRATOR, Department of Pharmacy, DEPARTMENT OF PHARMACY • Ahmed, Saveena, Budget Contact, Program Operations Analyst (E S 7), DEPARTMENT OF PHARMACY • Camp, Alyssa L, eGC1 Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY • Camp, Alyssa L, Advance Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY |
| A185722 | FA226901 | 67-4464 | 2021 | DRUG METABOLISM TG | Drug Action, Metabolism and Kinetics Training Grant | Non-Competing Renewal | Other Training: Research | Grant | 880005773 | ATKINS, WILLIAM M. | 3080003000 | MEDICINAL CHEMISTRY | SCHOOL OF PHARMACY | National Institute of General Medical Sciences (NIGMS) | DHHS-National Institutes of Health (NIH) | Yes | National Institute of General Medical Sciences (NIGMS) | $532,173 | 5T32GM007750-45 | Returned by GCA | 8.0 | 7/1/2023 | 6/30/2024 | 5/31/2023 | 2023 | A185722 | Professor | The primary objective of this Pharmacological Sciences Training Grant is to develop scientists, equipped with the necessary background in the biological and chemical sciences, and training in the application of modern tools of research and instrumental techniques, to undertake and direct fundamental research related to drug action, metabolism and kinetics.Trainees follow tracks that emphasize training in four broadly defined areas; (I) drug metabolism, (II) pharmacokinetics, drug transport and delivery, (III) cellular and molecular pharmacology and (IV) structure and drug design, that presently exist in the departments of Medicinal Chemistry, Pharmaceutics and Pharmacology.Didactic components involve individualized, highly multidisciplinary programs of coursework and seminars that center around the biological and chemical sciences. Research components of the program emphasize training in mechanistic and bioanalytical aspects of drug metabolism and toxicology, pharmacokinetics and pharmacodynamics, drug transporter function and regulation, pharmacogenetics, mechanisms and regulation of cell signaling, neuropharmacology and X-ray, NMR and proteomic approaches to structure elucidation of protein-ligand interactions of pharmacological interest. | Atkins, William M., Principal Investigator, Professor, MEDICINAL CHEMISTRY • Lee, Erik, Budget Contact, Budget/fiscal Analyst, MEDICINAL CHEMISTRY • Kanov, Jeanine M., eGC1 Preparer, ADMINISTRATOR, Department of Medicinal Chemistry, MEDICINAL CHEMISTRY • Catterall, William A, Mentor, Chair, PHARMACOLOGY • Chavkin, Charles, Mentor, Professor, PHARMACOLOGY • Cook, David G., Mentor, Adjunct Research Assoc Prof, PHARMACOLOGY • Gardner, Richard G., Mentor, Associate Professor, PHARMACOLOGY • Ho, Rodney J.Y., Mentor, Professor, PHARMACEUTICS |
| A166575 | FA227242 | 62-2033 | 2021 | BACS | Interactions between metabolism, transport, and toxicity of benzalkonium chlorides | New | Research: Basic | Grant | 849005600 | XU, LIBIN | 3080003000 | MEDICINAL CHEMISTRY | SCHOOL OF PHARMACY | National Institutes of Health (NIH) | DHHS-National Institutes of Health (NIH) | Yes | National Institutes of Health (NIH) | $463,606 | 5R01ES031927-03 | Processed | 55.5 | 9/1/2021 | 6/30/2026 | 6/2/2023 | 2023 | A166575 | Assistant Professor | Benzalkonium chlorides (BACs) are widely used as disinfectants and preservatives in cleaning products (Lysol, Clorox, hand sanitizer), medical products (eye drops and nasal spray), consumer products (cosmetics and personal care), and food processing industries, suggesting humans may be systemically exposed to BACs through a wide range of routes. Indeed, our preliminary study found that close to 50 of 100 random human plasma samples contain detectable levels of BACs, suggesting BACs can indeed be absorbed. The ongoing COVID-19 pandemic has led to greatly increased use of BAC-containing disinfectants, which is concerning given accumulating evidence in respiratory, developmental, reproductive, and neurological toxicities inflicted by BACs in rodents and BAC-induced disruption of cholesterol and lipid homeostasis in mice. However, there is a lack of knowledge on the metabolism, transport, and biological consequences of BACs in humans. We hypothesize that toxicities of BACs in liver and kidney are dependent on the activities of their metabolizing and transporting proteins. In this project, we will first characterize pathways of metabolism, transport, and toxicity of BACs in 2D cell culture and 3D microphysiological systems (“organ-on-a-chip”). We will then assess BAC exposure levels and correlate the exposure levels with sterol, lipid, and renal function biomarkers in humans. | Xu, Libin, Principal Investigator, Assistant Professor, MEDICINAL CHEMISTRY • Zhang, Rutan, Fellow, Senior Fellow, MEDICINAL CHEMISTRY • Seguin, Ryan Patrick, Fellow, Senior Fellow Trainee, MEDICINAL CHEMISTRY • Van Ness, Kirk Peter, Other, RESEARCH SCIENTIST/ENGINEER 2, PCEUT - KELLY LAB, PHARMACEUTICS • Macdonald, James, Other, RESEARCH SCIENTIST/ENGINEER 3, Enviro & Occup Heal, ENVIRO & OCCUP HEALTH • Thompson, Brice D, Other, Student Assistant (NE H), PHARMACEUTICS • Rettie, Allan E., Co-Investigator, Professor, MEDICINAL CHEMISTRY • Wang, Joanne, Co-Investigator, Professor, PHARMACEUTICS • Kelly, Edward J, Co-Investigator, Associate Professor, PHARMACEUTICS • Lin, Yvonne S., Co-Investigator, Associate Professor, PHARMACEUTICS • Kanov, Jeanine M., Administrative Contact, ADMINISTRATOR, Department of Medicinal Chemistry, MEDICINAL CHEMISTRY • Lidzbarski, Erik August Lee, Budget Contact, BUDGET/FISCAL ANALYST, MedChem - Admin, MEDICINAL CHEMISTRY • Kanov, Jeanine M., eGC1 Preparer, ADMINISTRATOR, Department of Medicinal Chemistry, MEDICINAL CHEMISTRY |
| A143603 | FA227696 | 62-3332 | 2021 | NIMH R01 HALISKI | Impact of Chronic Seizures on Neuropsychiatric Comorbidities in AD-Associated Models | Resubmission (Previously Denied) | Research: Basic | Grant | 847005064 | HALISKI, MELISSA | 3080001000 | DEPARTMENT OF PHARMACY | SCHOOL OF PHARMACY | National Institute of Mental Health (NIMH) | DHHS-National Institutes of Health (NIH) | Yes | National Institute of Mental Health (NIMH) | $388,750 | 5R01AG067788-04 | Processed | 55.5 | 9/15/2020 | 5/31/2025 | 6/8/2023 | 2023 | A143603 | Research Assistant Professor | Patients with Alzheimer’s disease (AD) experience seizures, although these events are commonly non-convulsive in nature and thus potentially missed. Despite this, little is known regarding the direct long-term impact of untreated seizures on disease progression in patients with AD. This study will directly define whether chronic seizures age-dependently aggravate cognitive and neuropsychiatric comorbidities of AD. | Haliski, Melissa, Principal Investigator, Research Assistant Professor, DEPARTMENT OF PHARMACY • Smith, Carole L., Other, RESEARCH SCIENTIST/ENGINEER 2, Neurology: Dr. Jaya, NEUROLOGY • Jayadev, Suman, Other, ASSOC PROFESSOR WITHOUT TENURE, Neurology: Neuroge, NEUROLOGY • Zierath, Dannielle, Other, Research Scientist/Engineer 3 (E S 8), NEUROLOGY • Knox, Kevin, Other, Research Scientist/Engineer 1 (E S 6), DEPARTMENT OF PHARMACY • Kimura, Maya, Administrative Contact, ADMINISTRATOR, Department of Pharmacy, DEPARTMENT OF PHARMACY • Ahmed, Saveena, Budget Contact, Program Operations Analyst (E S 7), DEPARTMENT OF PHARMACY • Camp, Alyssa L, eGC1 Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY |
| A158031 | FA224928 | 62-5217 | 2021 | UNADKAT_R01 BRAZIL-V2 | A Systems Pharmacology approach to predict the effects of pregnancy and infectious diseases on transporter-mediated drug disposition | Resubmission (Previously Denied) | Research: Basic | Grant | 866002370 | UNADKAT, JASHVANT D | 3080004000 | PHARMACEUTICS | SCHOOL OF PHARMACY | National Institutes of Health (NIH) | DHHS-National Institutes of Health (NIH) | Yes | National Institutes of Health (NIH) | $553,686 | 5R01HD102786-03 | Processed | 55.5 | 5/17/2021 | 4/30/2025 | 5/16/2023 | 2023 | A158031 | Milo Gibaldi Endowed Professorship In Pharmaceutic | Pregnancy and inflammation (due to infectious diseases) are each known to alter drug pharmacokinetics (PK) by changing the expression and activity of transporters and/or drug-metabolizing enzymes (e.g. CYPs). Quantifying changes in drug PK caused by pregnancy and/or cytokines (elevated during inflammation) is important for rational design of dosing regimens of drugs for pregnant women with infectious diseases. While changes in the PK of CYP-cleared drugs by pregnancy and cytokines have been well-delineated using CYP probe drugs, such data are sorely missing for transporters. However, obtaining data of changes in drug PK by pregnancy and/or pro-inflammatory infectious diseases for every possible transported drug administered to pregnant women (with or without infection) is logistically impossible. Therefore, alternative approaches that can generalize across drugs, transporters and pro-inflammatory infectious diseases are urgently needed. These approaches should accurately predict the alteration in in vivo activity of transporters by pregnancy and pro-inflammatory cytokines. In this proposal, we propose a systems pharmacology approach to predict the effects of pregnancy and/or pro-inflammatory infectious diseases on transporter-mediated drug PK. Our hypothesis is that the magnitude of change in drug PK by pregnancy and/or cytokines can be predicted through clinical PK studies using probe drugs and in vitro experimental data as well as Physiologically Based Pharmacokinetic (PBPK) modeling and simulation (M&S). While probe drugs can yield clinically significant and valuable data, transporter probe drugs, unlike CYP probe drugs, have the limitations that they are not selective. Therefore, to overcomethis limitation, we propose a two-pronged approach which utilizes both primary human cells (e.g. hepatocytes, renal epithelial cells, intestinal enterocytes) and transfected cells expressing individual transporters of interest. Using quantitative targeted proteomics, the human cells will allow us to determine the effect of pregnancy hormones or cytokines, on the expression of transporters in these cells. The transportertransfected cell studies will allow us to determine the intrinsic transport clearance of a drug by a single transporter per pmol of a transporter. Combined, these data will allow us to predict, through PBPK M&S,transporter-mediated clearance of drugs in pregnant women with and without infection. These studies will address a critical gap in our understanding of the effects of pregnancy and/or pro-inflammatory infectious diseases on transporter-mediated drug disposition. Since our approach can be applied to other drugs and other inflammatory diseases, its significance goes well beyond the drugs and inflammatory diseases investigated here. We would like this application to be considered under the NIH-FAPESP initiative (NOT-TW-16-001). Under this initiative, the clinical PK studies will be conducted in pregnant women with infectiousdiseases in Brazil, and the clinical PK data obtained will be used to verify our PBPK model predictions. | Unadkat, Jashvant D, Principal Investigator, Milo Gibaldi Endowed Professorship In Pharmaceutic, PHARMACEUTICS • Kelly, Ed, Key Personnel, Associate Professor, PHARMACEUTICS • Thummel, Kenneth E, Multiple PI, Professor, PHARMACEUTICS • Kirkpatrick, Leila, Administrative Contact, Grants And Contracts Manager/Specialist (E S 8), PHARMACEUTICS • Kirkpatrick, Leila, Budget Contact, Grants And Contracts Manager/Specialist (E S 8), PHARMACEUTICS • Kirkpatrick, Leila, eGC1 Preparer, Grants And Contracts Manager/Specialist (E S 8), PHARMACEUTICS |
| A163283 | FA227391 | 62-5487 | 2021 | IGM | Mechanisms of IgM mediated activation of the complement system | Resubmission (Previously Denied) | Research: Basic | Grant | 855001420 | GUTTMAN, MIKLOS | 3080003000 | MEDICINAL CHEMISTRY | SCHOOL OF PHARMACY | National Institutes of Health (NIH) | DHHS-National Institutes of Health (NIH) | Yes | National Institutes of Health (NIH) | $484,415 | 5R01AI153191-03 | Processed | 55.5 | 6/1/2021 | 5/31/2026 | 6/9/2023 | 2023 | A163283 | Assistant Professor | Antibodies are an integral part of the adaptive immune system and have become the major scaffold for modern biotherapeutics. Immunoglobulin (IgM) is the first antibody made in response to an infection and are present as natural antibodies that are critical for immunity during the early stages of development. Despite their critical importance, the structure of IgMs and how they mediate immune activation are poorly understood. The current proposal aims to utilize new structural techniques to unveil the molecular mechanisms of how IgM recognizes antigen and activates the immune system, which will provide critical insight into the development of a new class of biotherapeutics for treatment of cancers, infectious diseases, and autoimmune disorders. | Guttman, Miklos, Principal Investigator, Assistant Professor, MEDICINAL CHEMISTRY • Harkewicz, Richard, Other, Research Scientist/Engineer 3 (E S 8), MEDICINAL CHEMISTRY • Kollman, Justin M, Co-Investigator, Associate Professor, BIOCHEMISTRY • Kanov, Jeanine M., Administrative Contact, ADMINISTRATOR, Department of Medicinal Chemistry, MEDICINAL CHEMISTRY • Lidzbarski, Erik August Lee, Budget Contact, BUDGET/FISCAL ANALYST, MedChem - Admin, MEDICINAL CHEMISTRY • Kanov, Jeanine M., eGC1 Preparer, ADMINISTRATOR, Department of Medicinal Chemistry, MEDICINAL CHEMISTRY |
| A173780 | FA223671 | 62-6869 | 2021 | PGP2 | Drug, Nucleotide, and Lipid Interactions with P-glycoprotein | Resubmission (Previously Denied) | Research: Basic | Grant | 880005773 | ATKINS, WILLIAM M. | 3080003000 | MEDICINAL CHEMISTRY | SCHOOL OF PHARMACY | National Institutes of Health (NIH) | DHHS-National Institutes of Health (NIH) | Yes | National Institutes of Health (NIH) | $318,976 | 5R01GM144446-02 | Processed | 55.5 | 8/1/2022 | 4/30/2026 | 4/3/2023 | 2023 | A173780 | Professor | This proposal aims to understand fundamental mechanisms of the efflux transporter P-glycoprotein. P-glycoprotein pumps drugs and toxins from cells and plays a critical role in drug-drug and drug-food interactions. Increased mechanistic understanding of P-glycoprotein will facilitate prediction of drug-drug interactions and could aid in the development of new drugs. | Atkins, William M., Principal Investigator, Professor, MEDICINAL CHEMISTRY • Asbury, Charles L, Other, Professor, PHYSIOLOGY & BIOPHYSIC • Clouser, Amanda F., Other, Postdoctoral Scholar, MEDICINAL CHEMISTRY • Dabrowski, Michael J., Other, RESEARCH SCIENTIST/ENGINEER 2, MedChem - Atkins La, MEDICINAL CHEMISTRY • Vane, Eleanor Warner, Other, Postdoctoral Scholar, MEDICINAL CHEMISTRY • Mao, Qingcheng, Co-Investigator, Associate Professor, PHARMACEUTICS • Kanov, Jeanine M., Administrative Contact, ADMINISTRATOR, Department of Medicinal Chemistry, MEDICINAL CHEMISTRY • Lidzbarski, Erik August Lee, Budget Contact, BUDGET/FISCAL ANALYST, MedChem - Admin, MEDICINAL CHEMISTRY • Kanov, Jeanine M., eGC1 Preparer, ADMINISTRATOR, Department of Medicinal Chemistry, MEDICINAL CHEMISTRY |
| A179655 | FA223831 | 62-9579 | 2021 | SHIGELLA R01 RESUB | Pharmacokinetic and pharmacodynamic relationships for antibacterial treatment of shigellosis | Resubmission (Previously Denied) | Research: Basic | Grant | 854006153 | ARNOLD, SAMUEL L | 3080004000 | PHARMACEUTICS | SCHOOL OF PHARMACY | National Institutes of Health (NIH) | DHHS-National Institutes of Health (NIH) | Yes | National Institutes of Health (NIH) | $436,309 | 1R01AI170784-01A1 | Processed | 76.5 | 4/6/2023 | 3/31/2028 | 4/7/2023 | 2023 | A179655 | Assistant Professor | Enteric infection with Shigella spp. can lead to symptoms ranging from acute watery diarrhea to sudden, severe dysentery. Approximately 164,000 diarrheal deaths annually are attributed to Shigella (12.5% of total diarrheal deaths) with a disproportionate impact in low-middle income countries (LMIC). The impact in LMIC was recently illustrated by a reanalysis of the Global Enteric Multicenter Study (GEMS) which found that Shigella has the highest attributable fraction for diarrhea in children < 60 months. While recent studies have highlighted the burden of the disease, there has been a concurrent reduction in therapeutic options for the treatment of shigellosis as drug resistant strains increase in prevalence. In addition, increasing reports of drug resistant shigellosis cases in the men who has sex with men (MSM) community confirm that the impact isn’t limited to LMIC. Moving forward, there are critical gaps in the development of new shigellosis treatments. The long-term goals of the proposed work are to establish a rigorous pre-clinical framework which can be used to identify repurposing opportunities or new chemical entities for the treatment of shigellosis.Our previous innovative studies on the gut localized pathogen Cryptosporidium demonstrated the importance of gastrointestinal drug exposure for in vivo anti-Cryptosporidium efficacy. The pharmacokinetic/ pharmacodynamic (PK/PD) relationship for anti-Cryptosporidium drugs was characterized with in vitro and in vivo models of cryptosporidiosis. Our central hypothesis for this proposal is that a similar approach with in vitro and in vivo models can be used to establish the relationship between drug exposure and in vivo efficacy for shigellosis treatments. However, while there currently is no “gold standard” for the treatment of cryptosporidiosis in humans, there are a set of approved antibacterials with variable clinical efficacy against shigellosis in humans. Towards our hypothesis, we have initiated the development of in vitro and in vivo models of Shigella infection which can be used to characterize the efficacy of anti-Shigella therapeutics. The exciting preliminary data from these models suggest that they can be used to identify PK/PD relationships for antibacterials used to treat shigellosis. This crucial information will assist in our understanding of why the efficacy of antibacterials differ in the clinic. We propose to evaluate the PK/PD relationship for antibacterials by undertaking the following three Specific Aims: (1) To characterize the anti-Shigella efficacy of antibacterials with a panel of in vitro models. (2) To investigate the in vivo efficacy and pharmacokinetics of antibacterials to treat shigellosis. (3) To identify associations between antibacterial in vitro efficacy, pharmacokinetics, and in vivo efficacy.Taken together, these studies will help us better understand the current treatments for shigellosis and will provide a series of methods to identify new treatment options. In addition, the results of the work will provide fundamental support for drug discovery in infectious disease, especially in the area of enteric infections. | Arnold, Samuel L, Principal Investigator, Assistant Professor, DEPARTMENT OF MEDICINE • Barrett, Lynn K., Other, RESEARCH MANAGER, Department of Medicine: Allergy, DEPARTMENT OF MEDICINE • Zhang, Cindy Xinyi, Other, Research Assistant (E S UAW ASE), PHARMACEUTICS • Buckner, Frederick S., Co-Investigator, Professor without Tenure, DEPARTMENT OF MEDICINE • Emanuel, Kristen L., Administrative Contact, Administrator-Program Operations (E S 10), DEPARTMENT OF MEDICINE • Kirkpatrick, Leila, Budget Contact, Grants And Contracts Manager/Specialist (E S 8), PHARMACEUTICS • Lyle-Beshai, Katie, eGC1 Preparer, Program Operations Specialist (E S 7), DEPARTMENT OF MEDICINE • Damewood Gallagher, Andrea J, Budget Preparer, Program Operations Specialist (E S 7), DEPARTMENT OF MEDICINE • Kirkpatrick, Leila, Advance Preparer, Grants And Contracts Manager/Specialist (E S 8), PHARMACEUTICS |
| A185504 | FA227733 | 62-9727 | 2021 | R01 MRSA | Contribution of altered cell envelope metabolism to resistance to cell envelope-targeting antimicrobials in MRSA | Resubmission (Previously Denied) | Research: Basic | Grant | 850008495 | WERTH, BRIAN | 3080001000 | DEPARTMENT OF PHARMACY | SCHOOL OF PHARMACY | National Institutes of Health (NIH) | DHHS-National Institutes of Health (NIH) | Yes | National Institutes of Health (NIH) | $550,162 | 2R01AI136979-05A1 | Processed | 55.5 | 6/9/2023 | 5/31/2028 | 6/9/2023 | 2023 | A185504 | Associate Professor | Invasive infections due to the “superbug” methicillin-resistant Staphylococcus aureus (MRSA) have poor outcomes that are worsened by reduced susceptibility to first-line agents, vancomycin (glycopeptide; GP), and daptomycin (lipopeptide; LP). The long-acting lipoglycopeptide (LGP), dalbavancin, is an alternative that can be given weekly or as a single dose, which can facilitate discharge and reduce costs. However, we have shown that its long half-life may increase its resistance selection potential and can select for cross-resistance to vancomycin and daptomycin. Thus, there is a critical need to understand the mechanism(s) of cross-resistance among cell envelope-targeting drugs in MRSA and to investigate strategies to mitigate or overcome such resistance. Our work from the previous grant periods found that 75% of GP/LP/LGP non-susceptible isolates from in vitro PK/PD models simulating dalbavancin exposures acquired mutations related to the essential two-component regulatory system walKR. Furthermore, we recently published a case in which dalbavancin treatment selected for GP/LP/LGP-resistant MRSA in a patient with endocarditis, via a walK mutation. These recent findings led to the goal for this renewal: to elucidate the multiple mechanisms through which walKR mutations lead to GP/LP/LGP cross-resistance and reveal how beta-lactams and other metabolic modulators interact with WalKR-regulated metabolic networks to synergize with GP/LP/LGP and prevent resistance. We hypothesize that walKR mutations underlie GP/LP/LGP cross-resistance phenotypes through modulation of both cell envelope and nucleotide metabolism, and metabolic modulators can re-sensitize these strains to GP/LP/LGP or prevent resistance by further altering cell envelope or nucleotide metabolism. In AIM 1, we will measure the contribution of reduced WalKR function to cross-resistance phenotypes in MRSA using genetic, lipidomic, metabolomic, transcriptomic, and proteomic approaches in combination with susceptibility testing and quantitative biophysical assessment of the cell envelope properties. In AIM 2, we will test the hypothesis that beta-lactams and other metabolic modulators can re-sensitize walK-knockdown strains to GP/LP/LGP. We will examine the synergistic effects of cell wall inhibitors beta-lactams and fosfomycin, lipid synthesis inhibitors, and anti-folate drugs, trimethoprim/sulfamethoxazole, which will inform metabolic pathways that are important for walKR mutation-caused resistance. In AIM 3, we will evaluate the potential of beta-lactams and other metabolic modulators to prevent the selection of GP/LP/LGP resistance by dalbavancin in vitro using serial passage and PK/PD models. This work is significant because dalbavancin exposures readily select for vancomycin and daptomycin-resistant S. aureus and a strategy to prevent resistance and/or re-sensitize MRSA to GP/LG/LGP is critical to preserve these drugs, especially in the current context of increasing dalbavancin use. The innovation of this proposal includes leveraging metabolic phenotypes to inform and modulate resistance phenotypes and the application of high-throughput lipidomics and metabolomics to characterize drug resistance and responses. | Werth, Brian, Principal Investigator, Associate Professor, DEPARTMENT OF PHARMACY • SHULL, LAUREN MARIE, Fellow, Postdoctoral Scholar, MICROBIOLOGY • Zhang, Rutan, Fellow, Postdoctoral Scholar, MEDICINAL CHEMISTRY • BARRERAS BELTRAN, ISMAEL ARTURO, Other, Research Scientist/Engineer 1 (NE S 6), DEPARTMENT OF PHARMACY • Macdonald, James, Other, RESEARCH SCIENTIST/ENGINEER 3, Enviro & Occup Heal, ENVIRO & OCCUP HEALTH • Shen, Tianwei, Other, Research Assistant, MEDICINAL CHEMISTRY • Holston, Michelle L, Co-Investigator, Associate Professor, MICROBIOLOGY • Salipante, Stephen, Co-Investigator, Associate Professor without Tenure, LAB MEDICINE-PATHOLOGY • Xu, Libin, Multiple PI, Associate Professor, MEDICINAL CHEMISTRY • Kimura, Maya, Administrative Contact, ADMINISTRATOR, Department of Pharmacy, DEPARTMENT OF PHARMACY • Ahmed, Saveena, Budget Contact, Program Operations Analyst (E S 7), DEPARTMENT OF PHARMACY • Camp, Alyssa L, eGC1 Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY • Camp, Alyssa L, Budget Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY • Camp, Alyssa L, Advance Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY |
| A166855 | FA224635 | 63-7466 | 2021 | RIPS VANDERBILT | Rational Integration of Polygenic Risk Scores (RIPS) | New | Research: Applied | Grant | 867006453 | Veenstra, David | 3080001000 | DEPARTMENT OF PHARMACY | SCHOOL OF PHARMACY | Vanderbilt University Medical Center | Private School, College, University | No | National Institutes of Health (NIH) | $296,182 | VUMC100326 | Processed | 55.5 | 3/10/2022 | 2/29/2024 | 5/3/2023 | 2023 | A166855 | Professor | There has been extraordinary growth in the past years of new techniques to predict common, complex disease based on polygenic risk scores (PRS). Without an understanding grounded in evidence, it is unlikely that clinical sequencing using PRS will propagate from highly specialized applications and environments to become adopted more broadly and provide greater benefit to the US population. Critical challenges include: 1) identification of risk thresholds for return of results that optimize patient outcomes and provide cost-effective care, 2) uncertainty in generalizability of PRS performance across diverse populations and subsequent impact on patient outcomes, and 3) prioritization of future research to improve outcomes in diverse populations. We propose to address these challenges using decision analytic modeling and by building on our extensive work in this area to create a novel framework capable of assessing PRSs in the context of monogenic and clinical risks. Our Rational Integration of SEquencing (RISE) consortium has created clinical-economic models to project lifetime clinical impact and cost-effectiveness for population-level genomic screening with return of monogenic disease risks associated with three CDC Tier 1 conditions: hereditary breast and ovarian cancer, Lynch syndrome, and familial hyperlipidemia. We have found population genomic screening offers significant promise, but clinical benefit-harm tradeoffs must be carefully assessed and screening for multiple conditions will be needed to achieve cost effectiveness. As part of this proposal, titled Rational Integration of Polygenic Risk Scores (RIPS), will develop and execute a framework for assessing the clinical outcomes and economic value of comprehensive genomic screening using PRS in modeled real-world settings and applied to large and diverse populations. The Aims of the proposal include 1) to evaluate published and real-world evidence on the how returning genetic information impacts provider and patient behavior 2) to understand the impact of PRS performance and return thresholds on clinical benefit and cost-effectiveness for coronary artery disease (CAD), breast cancer, and colorectal cancer, and 3) To develop principles and research priorities for the equitable development and implementation of PRS across heterogenous populations. | Veenstra, David, Principal Investigator, Professor, DEPARTMENT OF PHARMACY • Guzauskas, Greg, Key Personnel, Research Scientist/Engineer 4 (E S 9), DEPARTMENT OF PHARMACY • Kimura, Maya, Administrative Contact, ADMINISTRATOR, Department of Pharmacy, DEPARTMENT OF PHARMACY • Ahmed, Saveena, Budget Contact, Program Operations Analyst (E S 7), DEPARTMENT OF PHARMACY • Camp, Alyssa L, eGC1 Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY • Camp, Alyssa L, Budget Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY • Camp, Alyssa L, Advance Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY |
| A187580 | FA222659 | 66-2746 | 2021 | SUPPLEMENT2TULANEGATES | Landscape analysis: Sentinel site readiness for Maternal Immunization Active Safety Surveillance in LMIC - Supplemental Project” | Supplement and Extension | Research: Applied | Grant | 874005710 | STERGACHIS, ANDREAS S | 3080001000 | DEPARTMENT OF PHARMACY | SCHOOL OF PHARMACY | Tulane University | Private School, College, University | No | Bill and Melinda Gates Foundation | $22,384 | TUL-HSC-560197-21/22 | Processed | 10.0 | 4/1/2022 | 12/31/2023 | 4/5/2023 | 2023 | A187580 | Professor | In this supplemental activity, University of Washington will provide guidance and expert advice on assessing the readiness for active safety surveillance. This contract is a supplement and extension of the current project. | Stergachis, Andreas S, Principal Investigator, Professor, DEPARTMENT OF PHARMACY • ZARAA, SABRA, Other, Graduate Research Student Assistant (NE H UAW ASE), DEPARTMENT OF PHARMACY • Kimura, Maya, Administrative Contact, ADMINISTRATOR, Department of Pharmacy, DEPARTMENT OF PHARMACY • Ahmed, Saveena, Budget Contact, Program Operations Analyst (E S 7), DEPARTMENT OF PHARMACY • Camp, Alyssa L, eGC1 Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY • Camp, Alyssa L, Advance Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY |
| A176225 | FA223345 | 66-9269 | 2021 | CARLSON MS TELEHEALTH | Clinical and Economic Impact of Teleneurology vs Standard in Clinic Care for Multiple Sclerosis: A Randomized Trial | Resubmission (Previously Denied) | Research: Applied | Grant | 863005316 | Carlson, Joshua J. | 3080001000 | DEPARTMENT OF PHARMACY | SCHOOL OF PHARMACY | Cleveland Clinic | Association & Non-Profits | No | National Institutes of Health (NIH) | $57,200 | CCF23314268 | Processed | 55.5 | 9/26/2022 | 6/30/2023 | 4/24/2023 | 2023 | A176225 | Assistant Professor | Cleveland Clinic has pioneered multiple sclerosis telehealth programs, and are looking to conduct a pilot project of telehealth versus conventional care, with a utilization and health economics primary outcome. | Carlson, Joshua J., Principal Investigator, Assistant Professor, DEPARTMENT OF PHARMACY • Kimura, Maya, Administrative Contact, ADMINISTRATOR, Department of Pharmacy, DEPARTMENT OF PHARMACY • Camp, Alyssa L, Budget Contact, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY • Camp, Alyssa, eGC1 Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY • Camp, Alyssa, Budget Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY • Camp, Alyssa L, Advance Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY |
| A164801 | FA226780 | 66-9933 | 2021 | MTAPS MOZAMBIQUE Y3 | USAID’s Medicines, Technologies, and Pharmaceutical Services Program (MTaPS) Mozambique Y3 | New | Research: Applied | Contract | 874005710 | Stergachis, Andreas S | 3080001000 | DEPARTMENT OF PHARMACY | SCHOOL OF PHARMACY | Management Sciences for Health (MSH) | Association & Non-Profits | No | US Agency for International Development (USAID) | $5,000 | MTaPS-20-037(PO#21MSH0327) | Processed | 55.5 | 12/22/2020 | 7/19/2023 | 5/23/2023 | 2023 | A164801 | Professor | In the Country Operational Plan (COP) 20, the national HIV and TB programs in Mozambique plan to scale up TB preventive therapy using 3HP based on updated guidance from the Centers for Disease Control and Prevention, that recommends use of a once weekly dose of isoniazid and rifapentine combination for 12 weeks (3HP) for the treatment of latent TB infection (LTBI) in HIV patients. The use of 3HP for TPT will be implemented alongside continued use of INH preventive therapy (IPT). The programs require technical assistance for the establishment of an active surveillance system to document adverse events that may be experienced by patients on INH and 3HP for TPT.In program year 3, MTaPS will build on the ongoing support to the National Directorate of Pharmacy (DNF) and HIV program on active surveillance to establish a similar system to actively monitor patients using INH and 3HP. The University of Washington is supporting the implementation of MTaPS’ pharmacovigilance (PV) activities, including previously supporting the implementation of an active surveillance system for the new DTG-based regimen in Mozambique. | Stergachis, Andreas S, Principal Investigator, Professor, DEPARTMENT OF PHARMACY • Kimura, Maya, Administrative Contact, ADMINISTRATOR, Department of Pharmacy, DEPARTMENT OF PHARMACY • Ahmed, Saveena, Budget Contact, Program Operations Analyst (E S 7), DEPARTMENT OF PHARMACY • Camp, Alyssa L, eGC1 Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY |
| A186243 | FA227280 | 68-7943 | 2023 | USPSTF - DEVINE GORE | Prostate Cancer Screening Topic Refinement for 2022 Systematic Review for the USPSTF - Group A | New | Research: Applied | Contract | 866006427 | Devine, Emily E. | 3080001000 | DEPARTMENT OF PHARMACY | SCHOOL OF PHARMACY | Oregon Health & Science University (OHSU) | Public School, College, University | No | Agency for Healthcare Research and Quality (AHRQ) | $34,118 | 1023803_UW | Processed | 55.5 | 6/1/2023 | 5/31/2024 | 6/8/2023 | 2023 | A186243 | Professor | AHRQ is commissioning a topic refinement on Prostate Cancer Screening on behalf of the USPSTF to be used by the Task Force to make recommendations on whether to update previous recommendations. The purpose of this large topic refinement will be to focus the scope to address the issues of most importance to the USPSTF. Our strategies include focusing on research gaps identified by prior USPSTF reviews and other reliable SERs, placing clinical experts on teams, and consulting with expert key informants to identify key issues that could be clarified with a SER, such as new or emerging diagnostic tests and interventions, as well as areas in which the evidence is well-established and may not require further review. | Devine, Emily E., Principal Investigator, Professor, DEPARTMENT OF PHARMACY • Gore, John L, Co-Investigator, Professor WOT, UROLOGY • Kimura, Maya, Administrative Contact, ADMINISTRATOR, Department of Pharmacy, DEPARTMENT OF PHARMACY • Ahmed, Saveena, Budget Contact, Program Operations Analyst (E S 7), DEPARTMENT OF PHARMACY • Camp, Alyssa L, eGC1 Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY • Camp, Alyssa L, Budget Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY • Camp, Alyssa L, Advance Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY |
| A177685 | FA224312 | 68-8026 | 2021 | UMASS R01 EBOLA | Dynamics and Mechanisms of Filovirus Envelope Glycoproteins | New | Research: Basic | Grant | 856002915 | LEE, KELLY K. | 3080003000 | MEDICINAL CHEMISTRY | SCHOOL OF PHARMACY | University of Massachusetts Chan Medical School | Public School, College, University | No | National Institutes of Health (NIH) | $94,202 | SUB00000294 | Processed | 55.5 | 9/19/2022 | 7/31/2023 | 6/6/2023 | 2023 | A177685 | Associate Professor | We are investigating structural dynamics and changes in structure in the Ebola virus fusion glycoprotein. This protein complex must undergo significant structural changes in response to signals it receives from receptor binding and changes in environmental conditions, such as following endocytosis. The nature of those structural and dynamic changes are largely unknown. The proposed combined study using single molecule Förster Resonance Energy Transfer (sm-FRET) microscopy and hydrogen/deuterium-exchange mass spectrometry should provide a powerful new understanding of how this virus’s fusion machinery is activated during cell entry, and can elucidate possible ways that the activation process can be inhibited by neutralizing antibodies or small molecule anti-viral compounds. | Lee, Kelly K., Principal Investigator, Associate Professor, MEDICINAL CHEMISTRY • Kanov, Jeanine M., Administrative Contact, ADMINISTRATOR, Department of Medicinal Chemistry, MEDICINAL CHEMISTRY • Lidzbarski, Erik August Lee, Budget Contact, BUDGET/FISCAL ANALYST, MedChem - Admin, MEDICINAL CHEMISTRY • Kanov, Jeanine M., eGC1 Preparer, ADMINISTRATOR, Department of Medicinal Chemistry, MEDICINAL CHEMISTRY • Kanov, Jeanine M., Budget Preparer, ADMINISTRATOR, Department of Medicinal Chemistry, MEDICINAL CHEMISTRY |
| A185942 | FA219497 | 68-8163 | 2021 | VILYA AGRMT - BHARDWAJ | Vilya, Inc. - Computational Approaches for Accurate Computational Design of Constrained Macrocycles | New | Research: Basic | Contract | 849003865 | BHARDWAJ, GAURAV | 3080003000 | MEDICINAL CHEMISTRY | SCHOOL OF PHARMACY | Vilya, Inc. | Private Industry | No | Vilya, Inc. | $500,000 | 52416A | Processed | 55.5 | 6/6/2023 | 6/5/2025 | 6/9/2023 | 2023 | A185942 | Assistant Professor | We previously developed methods for the accurate computational design of constrained peptides and structured macrocycles. These methods have recently been extended by us to identify the design principles for peptides with enhanced membrane permeability and oral bioavailability. While these methods enable precise control over the structure of macrocycles, further improvements to methods and energy functions are required to design macrocycles with desired functions and drug-like properties. Here we propose to develop an improved Rosetta-based energy function for macrocycle design and low-energy structure prediction. Overall, we will use these new energy functions and methods to create and assess diverse macrocyclic scaffolds. | Bhardwaj, Gaurav, Principal Investigator, Assistant Professor, MEDICINAL CHEMISTRY • Dimaio, Frank, Multiple PI, Associate Professor, BIOCHEMISTRY • Kanov, Jeanine M., Administrative Contact, ADMINISTRATOR, Department of Medicinal Chemistry, MEDICINAL CHEMISTRY • Camp, Alyssa L, Budget Contact, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY • Lidzbarski, Erik August Lee, eGC1 Preparer, BUDGET/FISCAL ANALYST, MedChem - Admin, MEDICINAL CHEMISTRY |
| A187366 | FA224308 | 80-1225 | 2021 | BRAMS WRF FELLOWSHIP | University of Washington BRAMS-WRF Regulatory Sciences Fellowship Program | New | Fellowship: Research Graduate/Professional | Grant | 859009180 | BOUGE, ALISHA | 3080001000 | DEPARTMENT OF PHARMACY | SCHOOL OF PHARMACY | Washington Research Foundation (WRF) | Foundation | No | Washington Research Foundation (WRF) | $30,000 | Processed | 0.0 | 4/17/2023 | 6/30/2025 | 5/1/2023 | 2023 | A187366 | Associate Teaching Professor | The BRAMS-WRF Regulatory Sciences Fellowship Program ('Program') supports the practicum component of selected students ('Fellows') enrolled in the Biomedical Regulatory Affairs Master of Science degree program (BRAMS), University of Washington. BRAMS requires a nine-credit practicum as a core component of the curriculum leading to the MS degree. Fellows selected for this Program typically assist with developing regulatory strategies for projects supported by WRF, under the guidance of a preceptor and assistance from BRAMS faculty. The immediate impact of this Program includes (a) students' gaining experience with real-world regulatory activities in fulfillment of graduation requirements and (b) guidance to the project principal investigator and WRF staff on how to move forward with the regulatory issues that the student has explored. Strengthening the regulatory affairs workforce is critical for success of the State of Washington's life sciences sector. | BOUGE, ALISHA, Principal Investigator, Associate Teaching Professor, DEPARTMENT OF PHARMACY • Johnson, Theodore Cassell, Key Personnel, Clinical Associate Professor - Non Salaried, DEPARTMENT OF PHARMACY • Kimura, Maya, Administrative Contact, ADMINISTRATOR, Department of Pharmacy, DEPARTMENT OF PHARMACY • Ahmed, Saveena, Budget Contact, Program Operations Analyst (E S 7), DEPARTMENT OF PHARMACY • Camp, Alyssa L, eGC1 Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY • Camp, Alyssa L, Budget Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY |
|
| A191887 | FA226855 | 80-1275 | 2021 | WITTENAUER AFPE FLWSHP | Wittenauer AFPE Predoctoral Fellowship | New | Fellowship: Research Graduate/Professional | Grant | 820003090 | WITTENAUER, RACHEL | 3080001000 | DEPARTMENT OF PHARMACY | SCHOOL OF PHARMACY | American Foundation for Pharmaceutical Education (AFPE) | Foundation | No | American Foundation for Pharmaceutical Education (AFPE) | $10,000 | Processed | 0.0 | 9/1/2023 | 8/31/2024 | 6/2/2023 | 2023 | A191887 | Research Assistant | Community pharmacies are a crucial component of US healthcare infrastructure. Communities that are both low-income and have low access to pharmacies are known as “pharmacy deserts” and lack access to the wide range of services that pharmacies provide.Pharmacy deserts disproportionately exist in rural or historically marginalized communities, compounding already-existing health inequities experienced by these communities. Information is lacking on the specific locations of these deserts nationwide, making itdifficult to measure both the detrimental effects of poor access and the beneficial effects of pharmacy-based health interventions and services across geography. These detrimental effects may include lower use of pharmacy-based patient careservices, including vaccinations. Low coverage of adult vaccinations in the US is a persistent problem, consistently falling short of the Healthy People 2030 goals and causing substantial health and economic consequences. While primary care providers (PCPs) are the main provider of childhood vaccinations, pharmacies are vital access points and providers for adult vaccinations.Pharmacies provide: 98% of shingles vaccines, more seasonal influenza vaccines than PCPs, and nearly half of all COVID-19 vaccines. Physical access to pharmacies may not always equate to access to pharmacy-based services. In April 2021, a national-level bill was introduced in the US Congress to address a key policy reform for pharmacists: establishment of “provider status,” which would align insurance reimbursement with valuable patient care services that pharmacists are currently providing with little or no compensation. Unlike other allied health professionals (e.g., nurse practitioners, clinical psychologists),37 pharmacists can only use billing codes under insurance plans’ prescription drug benefit (ingredient costs and dispensing fees), but not the medical benefit(patient care services). This creates a financial disincentive for pharmacists to provide these important services. Seven states, including Washington, have enacted provider status legislation, which recognizes pharmacists as “providers” for commercial and Medicaid insurance, creating a natural experiment to explore the effects of these policies on patient health outcomes, for which evidence is currently lacking. Shingles vaccination is a patient service that is primarily provided in pharmacies (as opposed to in PCPs) and is also provided to patients with commercial insurance (as opposed to solely Medicare) and thus potentially affected by state-level “provider status” payment regulations. These two characteristics make shingles vaccination an ideal patient service to examine with respect to the effects of pharmacy access and reimbursement laws. | Wittenauer, Rachel, Principal Investigator, Research Assistant (E S UAW ASE), GLOBAL HEALTH • Kimura, Maya, Administrative Contact, ADMINISTRATOR, Department of Pharmacy, DEPARTMENT OF PHARMACY • Ahmed, Saveena, Budget Contact, Program Operations Analyst (E S 7), DEPARTMENT OF PHARMACY • Camp, Alyssa, eGC1 Preparer, , DEPARTMENT OF PHARMACY • Camp, Alyssa L, Budget Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY |
|
| A186940 | FA223418 | 80-1290 | 2021 | KHOR AFPE PRE-DOC FSHP | AFPE Pre-Doctoral Fellowship in Pharmaceutical Sciences Application | Competing Renewal | Fellowship: Research Graduate/Professional | Grant | 863005316 | CARLSON, JOSHUA J. | 3080001000 | DEPARTMENT OF PHARMACY | SCHOOL OF PHARMACY | American Foundation for Pharmaceutical Education (AFPE) | Foundation | No | American Foundation for Pharmaceutical Education (AFPE) | $10,000 | Processed | 0.0 | 9/1/2023 | 8/31/2024 | 6/8/2023 | 2023 | A186940 | Associate Professor | The overall objective of Dr. Khor's dissertation is to develop an understanding of how to incorporate health equity considerations into medical decisions. AIM 1: Examine the relationship between the introduction of new oncologic drugs and disparities in health and economic outcomes. AIM 2: Compare the long-term impacts of adopting race-conscious vs. race-neutral prediction algorithms into clinical care on health disparities. AIM 3: Examine the US public’s stated preferences for health equity when confronted with an equity-efficiency tradeoff | Carlson, Joshua J., Principal Investigator, Associate Professor, DEPARTMENT OF PHARMACY • Khor, Sara, Fellow, Research Assistant (E S UAW ASE), DEPARTMENT OF PHARMACY • Kimura, Maya, Administrative Contact, ADMINISTRATOR, Department of Pharmacy, DEPARTMENT OF PHARMACY • Ahmed, Saveena, Budget Contact, Program Operations Analyst (E S 7), DEPARTMENT OF PHARMACY • Camp, Alyssa L, eGC1 Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY • Camp, Alyssa L, Budget Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY |
|
| A181595 | FA215888 | 80-1686 | 2021 | GENENTECH STELLA KO | Genentech Fellowship 2022-2024 | New | Fellowship: Non-Research Graduate/Professional | Contract | 867006453 | VEENSTRA, DAVID | 3080001000 | DEPARTMENT OF PHARMACY | SCHOOL OF PHARMACY | Genentech, Inc. | Private Industry | No | Genentech, Inc. | $261,681 | Processed | 25.0 | 7/1/2022 | 6/30/2024 | 4/12/2023 | 2023 | A181595 | Professor | This Fellowship Program is a two year program designed to train clinical pharmacists in the fields of health outcomes, health economics, technology assessment, and reimbursement policies and prepare them for research scientists and/or management roles in a setting where the broadly defined field of HEOR is the primary focus and application within health systems is emphasized. The Fellow will be supervised by a faculty member at the University of Washington in the Comparative Health Outcomes, Policy & Economics (CHOICE) Institute while at the university, and by an E4A Health Economist from US Medical Affairs, Evidence for Access Medical Unit while on rotation at Genentech. | Veenstra, David, Principal Investigator, Professor, DEPARTMENT OF PHARMACY • Bansal, Aasthaa, Key Personnel, Associate Professor, DEPARTMENT OF PHARMACY • Ko, Young Eun, Fellow, Postdoctoral Scholar Fellow, DEPARTMENT OF PHARMACY • Kimura, Maya, Administrative Contact, ADMINISTRATOR, Department of Pharmacy, DEPARTMENT OF PHARMACY • Ahmed, Saveena, Budget Contact, Program Operations Analyst (E S 7), DEPARTMENT OF PHARMACY • Camp, Alyssa L, eGC1 Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY • Camp, Alyssa L, Advance Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY |
|
| A181597 | FA215890 | 80-1687 | 2021 | GENENTECH SPENCERCHENG | Genentech Fellowship 2022-2024 | New | Fellowship: Non-Research Graduate/Professional | Contract | 867006453 | VEENSTRA, DAVID | 3080001000 | DEPARTMENT OF PHARMACY | SCHOOL OF PHARMACY | Genentech, Inc. | Private Industry | No | Genentech, Inc. | $261,681 | Processed | 25.0 | 7/1/2022 | 6/30/2024 | 4/12/2023 | 2023 | A181597 | Professor | This Fellowship Program is a two year program designed to train clinical pharmacists in the fields of health outcomes, health economics, technology assessment, and reimbursement policies and prepare them for research scientists and/or management roles in a setting where the broadly defined field of HEOR is the primary focus and application within health systems is emphasized. The Fellow will be supervised by a faculty member at the University of Washington in the Comparative Health Outcomes, Policy & Economics (CHOICE) Institute while at the university, and by an E4A Health Economist from US Medical Affairs, Evidence for Access Medical Unit while on rotation at Genentech. | Veenstra, David, Principal Investigator, Professor, DEPARTMENT OF PHARMACY • Bansal, Aasthaa, Key Personnel, Associate Professor, DEPARTMENT OF PHARMACY • CHENG, SPENCER JANE, Fellow, Postdoctoral Scholar Fellow, DEPARTMENT OF PHARMACY • Kimura, Maya, Administrative Contact, ADMINISTRATOR, Department of Pharmacy, DEPARTMENT OF PHARMACY • Ahmed, Saveena, Budget Contact, Program Operations Analyst (E S 7), DEPARTMENT OF PHARMACY • Camp, Alyssa L, eGC1 Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY • Camp, Alyssa L, Advance Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY |
|
| A127675 | FA212450 | 66-4707 | 2021 | SUPERINFECTION SUB | Characterizing the broad antibody response to HIV superinfection | New | Research: Basic | Grant | 856002915 | LEE, KELLY K. | 3080003000 | MEDICINAL CHEMISTRY | SCHOOL OF PHARMACY | Fred Hutchinson Cancer Research Center (FHCRC) | Association & Non-Profits | No | National Institutes of Health (NIH) | $109,371 | 0001114230 | Returned by GCA | 55.5 | 4/1/2022 | 1/31/2023 | 8/19/2022 | 2023 | A127675 | Associate Professor | A collaborative effort between the UW Lee lab and Fred Hutchinson Cancer Research Center lab’s led by Dr. Julie Overbaugh and colleagues, Drs. Jesse Bloom and Frederick Matsen will apply state-of-the-art structural, biophysical, and evolutionary analytical methods to understand the development of virus neutralization breadth in the context of HIV superinfection. | Lee, Kelly K., Principal Investigator, Associate Professor, MEDICINAL CHEMISTRY • Kanov, Jeanine M., Administrative Contact, ADMINISTRATOR, Department of Medicinal Chemistry, MEDICINAL CHEMISTRY • Lee, Erik, Budget Contact, BUDGET/FISCAL ANALYST, MedChem - Admin, MEDICINAL CHEMISTRY • Kanov, Jeanine M., eGC1 Preparer, ADMINISTRATOR, Department of Medicinal Chemistry, MEDICINAL CHEMISTRY • Lidzbarski, Erik August Lee, Advance Preparer, BUDGET/FISCAL ANALYST, MedChem - Admin, MEDICINAL CHEMISTRY |
| A127819 | FA215387 | 61-5588 | 2021 | PRAISE | Personalized Risk-AdaptIve Surveillance strategies in cancEr (PRAISE) | Resubmission (Previously Denied) | Research: Basic | Grant | 859002839 | BANSAL, AASTHAA | 3080001000 | DEPARTMENT OF PHARMACY | SCHOOL OF PHARMACY | National Institutes of Health (NIH) | DHHS-National Institutes of Health (NIH) | Yes | National Institutes of Health (NIH) | $419,114 | 5R37CA218413-05 | Processed | 55.5 | 9/1/2018 | 8/31/2023 | 8/17/2022 | 2023 | A127819 | Research Assistant Professor | This research addresses a significant problem in cancer survivorship care by using novel approaches and developing a practical tool to help resolve the uncertainty that clinicians and patients face when confronted with using new and evolving biomarker technologies to monitor for recurrence after patients have survived their primary cancer. Our holistic approach of applying the decision-making framework to three wide ranging cancer applications will inform both clinical decision-making in these areas and also future policy decisions on research investments with a transparent link between the needs for additional biomarker development and improving population outcomes. | Bansal, Aasthaa, Principal Investigator, Research Assistant Professor, DEPARTMENT OF PHARMACY • Basu, Anirban, Co-Investigator, Professor, DEPARTMENT OF PHARMACY • Veenstra, David, Co-Investigator, Professor, DEPARTMENT OF PHARMACY • Heagerty, Patrick J., Co-Investigator, Professor, N/A • Shankaran, Veena, Co-Investigator, Assoc Professor Without Tenure, DEPARTMENT OF MEDICINE • Inoue, Lurdes, Co-Investigator, Professor, N/A • Kimura, Maya, Administrative Contact, ADMINISTRATOR, Department of Pharmacy, DEPARTMENT OF PHARMACY • Camp, Alyssa L, Budget Contact, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY • Camp, Alyssa L, eGC1 Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY • Ahmed, Saveena, Budget Preparer, Program Operations Analyst (E S 7), DEPARTMENT OF PHARMACY • Luetjen, Karen H., Advance Preparer, GRANTS AND CONTRACTS MANAGER/SPECIALIST, Pharm - A, DEPARTMENT OF PHARMACY |
| A166575 | FA213517 | 62-2033 | 2021 | BACS | Interactions between metabolism, transport, and toxicity of benzalkonium chlorides | New | Research: Basic | Grant | 849005600 | XU, LIBIN | 3080003000 | MEDICINAL CHEMISTRY | SCHOOL OF PHARMACY | DHHS-National Institutes of Health (NIH) | Yes | National Institutes of Health (NIH) | $463,606 | 5R01ES031927-02 | Processed | 55.5 | 9/10/2021 | 6/30/2026 | 7/12/2022 | 2023 | A166575 | Assistant Professor | Benzalkonium chlorides (BACs) are widely used as disinfectants and preservatives in cleaning products (Lysol, Clorox, hand sanitizer), medical products (eye drops and nasal spray), consumer products (cosmetics and personal care), and food processing industries, suggesting humans may be systemically exposed to BACs through a wide range of routes. Indeed, our preliminary study found that close to 50 of 100 random human plasma samples contain detectable levels of BACs, suggesting BACs can indeed be absorbed. The ongoing COVID-19 pandemic has led to greatly increased use of BAC-containing disinfectants, which is concerning given accumulating evidence in respiratory, developmental, reproductive, and neurological toxicities inflicted by BACs in rodents and BAC-induced disruption of cholesterol and lipid homeostasis in mice. However, there is a lack of knowledge on the metabolism, transport, and biological consequences of BACs in humans. We hypothesize that toxicities of BACs in liver and kidney are dependent on the activities of their metabolizing and transporting proteins. In this project, we will first characterize pathways of metabolism, transport, and toxicity of BACs in 2D cell culture and 3D microphysiological systems (“organ-on-a-chip”). We will then assess BAC exposure levels and correlate the exposure levels with sterol, lipid, and renal function biomarkers in humans. | Xu, Libin, Principal Investigator, Assistant Professor, MEDICINAL CHEMISTRY • Zhang, Rutan, Fellow, Senior Fellow, MEDICINAL CHEMISTRY • Seguin, Ryan Patrick, Fellow, Senior Fellow Trainee, MEDICINAL CHEMISTRY • Van Ness, Kirk Peter, Other, RESEARCH SCIENTIST/ENGINEER 2, PCEUT - KELLY LAB, PHARMACEUTICS • Macdonald, James, Other, RESEARCH SCIENTIST/ENGINEER 3, Enviro & Occup Heal, ENVIRO & OCCUP HEALTH • Thompson, Brice D, Other, Student Assistant (NE H), PHARMACEUTICS • Rettie, Allan E., Co-Investigator, Professor, MEDICINAL CHEMISTRY • Wang, Joanne, Co-Investigator, Professor, PHARMACEUTICS • Kelly, Edward J, Co-Investigator, Associate Professor, PHARMACEUTICS • Lin, Yvonne S., Co-Investigator, Associate Professor, PHARMACEUTICS • Kanov, Jeanine M., Administrative Contact, ADMINISTRATOR, Department of Medicinal Chemistry, MEDICINAL CHEMISTRY • Lidzbarski, Erik August Lee, Budget Contact, BUDGET/FISCAL ANALYST, MedChem - Admin, MEDICINAL CHEMISTRY • Kanov, Jeanine M., eGC1 Preparer, ADMINISTRATOR, Department of Medicinal Chemistry, MEDICINAL CHEMISTRY |
|
| A143603 | FA212893 | 62-3332 | 2021 | NIMH R01 HALISKI | Impact of Chronic Seizures on Neuropsychiatric Comorbidities in AD-Associated Models | Resubmission (Previously Denied) | Research: Basic | Grant | 847005064 | HALISKI, MELISSA | 3080001000 | DEPARTMENT OF PHARMACY | SCHOOL OF PHARMACY | National Institute of Mental Health (NIMH) | DHHS-National Institutes of Health (NIH) | Yes | National Institute of Mental Health (NIMH) | $388,750 | 5R01AG067788-03 | Processed | 55.5 | 9/15/2020 | 5/31/2025 | 7/13/2022 | 2023 | A143603 | Research Assistant Professor | Patients with Alzheimer’s disease (AD) experience seizures, although these events are commonly non-convulsive in nature and thus potentially missed. Despite this, little is known regarding the direct long-term impact of untreated seizures on disease progression in patients with AD. This study will directly define whether chronic seizures age-dependently aggravate cognitive and neuropsychiatric comorbidities of AD. | Haliski, Melissa, Principal Investigator, Research Assistant Professor, DEPARTMENT OF PHARMACY • Smith, Carole L., Other, RESEARCH SCIENTIST/ENGINEER 2, Neurology: Dr. Jaya, NEUROLOGY • Jayadev, Suman, Other, ASSOC PROFESSOR WITHOUT TENURE, Neurology: Neuroge, NEUROLOGY • Zierath, Dannielle, Other, Research Scientist/Engineer 3 (E S 8), NEUROLOGY • Knox, Kevin, Other, Research Scientist/Engineer 1 (E S 6), DEPARTMENT OF PHARMACY • Kimura, Maya, Administrative Contact, ADMINISTRATOR, Department of Pharmacy, DEPARTMENT OF PHARMACY • Ahmed, Saveena, Budget Contact, Program Operations Analyst (E S 7), DEPARTMENT OF PHARMACY • Camp, Alyssa L, eGC1 Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY |
| A160216 | FA213836 | 62-3885 | 2021 | FERRARI_INPG-PDOX | A Nanodrug for the Cure of Metastatic Breast Cancer | Non-Competing Revision | Research: Basic | Grant | 818006294 | FERRARI, MAURO | 3080004000 | PHARMACEUTICS | SCHOOL OF PHARMACY | US Army Medical Research and Materiel Command (USAMRMC) | Department of Defense | Yes | US Army Medical Research and Materiel Command (USAMRMC) | $1,530,579 | W81XWH-17-1-0389 | Processed | 55.5 | 11/1/2020 | 10/31/2023 | 8/8/2022 | 2023 | A160216 | Affiliate Professor | The Objectives of this application are: 1) to complete GLP safety studies of iNPG-pDox in two animals species in support of an IND filing with the FDA; 2) to secure approval by the US FDA for clinical trials of iNPG-pDox for the treatment of TNBC with visceral metastasis; 3) to perform a Phase I clinical trial to determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and other toxicities possibly associated with iNPG-pDox in patients with TNBC visceral metastasis; and 4) to conduct a Phase II clinical trial to evaluate the ORR, efficacy, and safety of iNPG-pDox in TNBC patients. Our central hypothesis is that iNPG-pDox will prove safe and provide long-term survival benefits (disease-free outcomes) in patients, where the drug is able to penetrate the relevant biological barriers and localize treatment on the metastatic lesions – resulting in a breakthrough treatment option for patients with few to no effective alternatives. | Ferrari, Mauro, Principal Investigator, Affiliate Professor, PHARMACEUTICS • Ho, Rodney J.Y., Key Personnel, Professor, PHARMACEUTICS • Kirkpatrick, Leila, Administrative Contact, Grants And Contracts Manager/Specialist (E S 8), PHARMACEUTICS • Kirkpatrick, Leila, Budget Contact, Grants And Contracts Manager/Specialist (E S 8), PHARMACEUTICS • Kirkpatrick, Leila, eGC1 Preparer, Grants And Contracts Manager/Specialist (E S 8), PHARMACEUTICS |
| A179780 | FA215694 | 62-6774 | 2021 | UWPKDAP RPPR | Pharmacology of Drugs of Abuse During Pregnancy | Non-Competing Renewal | Research: Applied | Grant | 866002370 | UNADKAT, JASHVANT D | 3080004000 | PHARMACEUTICS | SCHOOL OF PHARMACY | National Institutes of Health (NIH) | DHHS-National Institutes of Health (NIH) | Yes | National Institutes of Health (NIH) | $1,475,139 | 5P01DA032507-09 | Processed | 55.5 | 8/1/2022 | 7/31/2023 | 8/29/2022 | 2023 | A179780 | Professor | Use of marijuana amongst pregnant women in the US is increasing. A major concern of marijuana use by pregnant women is the transfer of cannabinoids across the placental barrier, leading to placental (and therefore fetal) toxicity. Studies proposed in this P01 will elucidate how and to what extent the maternal-placental-fetal exposure to cannabinoids is altered during pregnancy and how to predict these changes. Completion of these studies will significantly advance our ability to predict the risks of using marijuana during pregnancy and have the potential to reveal strategies to minimize such risks. This P01 addresses a significant public health problem that cannot be addressed using the traditional approach of conducting a clinical trial. | Unadkat, Jashvant D, Principal Investigator, Professor, PHARMACEUTICS • Isoherranen, Nina, Co-Investigator, Professor, PHARMACEUTICS • Mao, Qingcheng, Co-Investigator, Associate Professor, PHARMACEUTICS • Kelly, Edward J, Co-Investigator, Associate Professor, PHARMACEUTICS • Rubinow, Katya B., Co-Investigator, Associate Professor WOT, DEPARTMENT OF MEDICINE • Amory, John K., Co-Investigator, Professor, DEPARTMENT OF MEDICINE • Kirkpatrick, Leila, Administrative Contact, Grants And Contracts Manager/Specialist (E S 8), PHARMACEUTICS • Kirkpatrick, Leila, Budget Contact, Grants And Contracts Manager/Specialist (E S 8), PHARMACEUTICS • Kirkpatrick, Leila, eGC1 Preparer, Grants And Contracts Manager/Specialist (E S 8), PHARMACEUTICS • Kirkpatrick, Leila, Advance Preparer, Grants And Contracts Manager/Specialist (E S 8), PHARMACEUTICS |
| A168377 | FA213326 | 62-6811 | 2021 | TRANS ESTROGEN STUDY | Hormone mediated mechanisms of altered drug metabolism and transport in transgender adults | New | Research: Applied | Grant | 819004241 | Cirrincione, Lauren | 3080001000 | DEPARTMENT OF PHARMACY | SCHOOL OF PHARMACY | National Institutes of Health (NIH) | DHHS-National Institutes of Health (NIH) | Yes | National Institutes of Health (NIH) | $187,056 | 1 K23 GM 147350-01 | Processed | 8.0 | 8/1/2022 | 7/31/2026 | 7/28/2022 | 2023 | A168377 | Assistant Professor | Worldwide nearly 25 million adults are part of a growing population of transgender people. Many transgender adults undergo hormone therapy as one part of the standard of medical care, but the effect of high dose sex hormone therapy on drug safety and efficacy has not been established. This project aims to evaluate the effect of estradiol treatment on the activities of cytochrome P450 3A and P-glycoprotein activities, two key drug handling proteins, to establish the effect of gender-affirming hormone therapy on drug disposition in transgender adults. | Cirrincione, Lauren, Principal Investigator, Assistant Professor, DEPARTMENT OF PHARMACY • Micks, Elizabeth A, Key Personnel, Associate Professor without Tenure, OBGYN/ADMIN • Bansal, Aasthaa, Other, Associate Professor, DEPARTMENT OF PHARMACY • Anawalt, Bradley D, Other, Professor without Tenure, DEPARTMENT OF MEDICINE • Hebert, Mary F, Mentor, Professor, DEPARTMENT OF PHARMACY • Thummel, Kenneth E., Mentor, Professor, PHARMACEUTICS • Kimura, Maya, Administrative Contact, ADMINISTRATOR, Department of Pharmacy, DEPARTMENT OF PHARMACY • Ahmed, Saveena, Budget Contact, Program Operations Analyst (E S 7), DEPARTMENT OF PHARMACY • Camp, Alyssa L, eGC1 Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY • Camp, Alyssa L, Budget Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY • Camp, Alyssa L, Advance Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY |
| A173966 | FA214241 | 62-6831 | 2021 | HIV VLP FUSION | Lipid Bilayer Remodeling and Protein Intermediates During Membrane Fusion | Resubmission (Previously Denied) | Research: Basic | Grant | 856002915 | LEE, KELLY K. | 3080003000 | MEDICINAL CHEMISTRY | SCHOOL OF PHARMACY | National Institutes of Health (NIH) | DHHS-National Institutes of Health (NIH) | Yes | National Institutes of Health (NIH) | $597,847 | 1R01AI165808-01A1 | Processed | 55.5 | 7/25/2022 | 6/30/2026 | 7/26/2022 | 2023 | A173966 | Associate Professor | Protein-mediated membrane fusion is a fundamental process that is essential for biological functions as wide ranging as gamete fertilization, formation of placenta, synaptic vesicle trafficking, tissue development, mitochondrial function, and enveloped virus infection. Despite its significance, little is understood at a mechanistic and structural level regarding how specialized fusion protein machinery and membranes interact in order to go from a prefusion to activated fusogenic to fusion pore formation state. Here cryo-electron microscopy and structural mass spectrometry will be used to study membrane fusion in two highly divergent enveloped viruses, thus providing new insights into how very different protein machines accomplish similar physical functions of merging two distinct membranes into one. | Lee, Kelly K., Principal Investigator, Associate Professor, MEDICINAL CHEMISTRY • Kanov, Jeanine M., Administrative Contact, ADMINISTRATOR, Department of Medicinal Chemistry, MEDICINAL CHEMISTRY • Lidzbarski, Erik August Lee, Budget Contact, BUDGET/FISCAL ANALYST, MedChem - Admin, MEDICINAL CHEMISTRY • Kanov, Jeanine M., eGC1 Preparer, ADMINISTRATOR, Department of Medicinal Chemistry, MEDICINAL CHEMISTRY • Kanov, Jeanine M., Budget Preparer, ADMINISTRATOR, Department of Medicinal Chemistry, MEDICINAL CHEMISTRY |
| A173780 | FA214454 | 62-6869 | 2021 | PGP2 | Drug, Nucleotide, and Lipid Interactions with P-glycoprotein | Resubmission (Previously Denied) | Research: Basic | Grant | 880005773 | ATKINS, WILLIAM M. | 3080003000 | MEDICINAL CHEMISTRY | SCHOOL OF PHARMACY | National Institutes of Health (NIH) | DHHS-National Institutes of Health (NIH) | Yes | National Institutes of Health (NIH) | $318,976 | 1 R01 GM 144446-01A1 | Processed | 55.5 | 8/1/2022 | 4/30/2026 | 7/28/2022 | 2023 | A173780 | Professor | This proposal aims to understand fundamental mechanisms of the efflux transporter P-glycoprotein. P-glycoprotein pumps drugs and toxins from cells and plays a critical role in drug-drug and drug-food interactions. Increased mechanistic understanding of P-glycoprotein will facilitate prediction of drug-drug interactions and could aid in the development of new drugs. | Unadkat, Jashvant D, Principal Investigator, Professor, PHARMACEUTICS • Isoherranen, Nina, Co-Investigator, Professor, PHARMACEUTICS • Mao, Qingcheng, Co-Investigator, Associate Professor, PHARMACEUTICS • Kelly, Edward J, Co-Investigator, Associate Professor, PHARMACEUTICS • Rubinow, Katya B., Co-Investigator, Associate Professor WOT, DEPARTMENT OF MEDICINE • Amory, John K., Co-Investigator, Professor, DEPARTMENT OF MEDICINE • Kirkpatrick, Leila, Administrative Contact, Grants And Contracts Manager/Specialist (E S 8), PHARMACEUTICS • Kirkpatrick, Leila, Budget Contact, Grants And Contracts Manager/Specialist (E S 8), PHARMACEUTICS • Kirkpatrick, Leila, eGC1 Preparer, Grants And Contracts Manager/Specialist (E S 8), PHARMACEUTICS • Kirkpatrick, Leila, Advance Preparer, Grants And Contracts Manager/Specialist (E S 8), PHARMACEUTICS |
| A179483 | FA216189 | 62-6968 | 2021 | HO U01_WE REACH Y4 | Washington Entrepreneurial Research Evaluation and Commercialization Hub | Non-Competing Renewal | Research: Basic | Cooperative Agreement | 867006435 | HO, RODNEY J.Y. | 3080004000 | PHARMACEUTICS | SCHOOL OF PHARMACY | National Institutes of Health (NIH) | DHHS-National Institutes of Health (NIH) | Yes | National Institutes of Health (NIH) | $994,469 | 5U01HL152401-04 | Processed | 55.5 | 9/1/2022 | 8/31/2023 | 9/6/2022 | 2023 | A179483 | Professor | The overarching goal of the partnership between NIH and the University of Washington (UW) Entrepreneurial Research Evaluation and Commercialization Hub (referred to as WE-REACH) is to facilitate and accelerate the transformation of health research innovations into products and services that address unmet medical needs. We will accomplish this through the following aims: 1. Develop innovative, synergistic and integrated infrastructure and implementation systems2. Identify the most promising technologies and increase their impact through the provision of gap funding, resources and mentoring (in business, marketing, networking and assessing funding) for proof-of-concept and product definition3. Fuel the formation of new biotech, pharma and medical device companies and assist in pathways to a self-sustaining structure 4. Train the next generation of biomedical-entrepreneurs to lead these ventures. | Ho, Rodney J.Y., Principal Investigator, Professor, PHARMACEUTICS • Stergachis, Andreas S, Key Personnel, Professor, DEPARTMENT OF PHARMACY • Patel, Shwetak Naran, Key Personnel, Professor, COMPUTER SCIENCE & ENG • Baker, David, Key Personnel, PROFESSOR, Biochemistry, BIOCHEMISTRY • Disis, Mary L., Key Personnel, Professor without Tenure, DEPARTMENT OF MEDICINE • Wills, Fiona L, Key Personnel, DIRECTOR, CoMotion, COMOTION • Sun, Tong, Key Personnel, DIRECTOR, DEANS: Institute of Translational Health, ITHS • Ingram, Jonathan B, Other, Program Operations Specialist (E S 7), PHARMACEUTICS • Hartman, Matthew H, Other, Program Operations Specialist (E S 7), PHARMACEUTICS • Butler, Terri Larson, Other, Program Operations Specialist (E S 9), PHARMACEUTICS • Ransom, Scott, Other, MANAGER OF PROGRAM OPERATIONS, Computer Science &, COMPUTER SCIENCE & ENG • Fukuda, Yuichi, Other, Program Operations Specialist (E S 7), PHARMACEUTICS • Jonsson, Christine Anne, Administrative Contact, MANAGER OF PROGRAM OPERATIONS, Department of Medic, DEPARTMENT OF MEDICINE • Fukuda, Yuichi, Budget Contact, Program Operations Specialist (E S 7), PHARMACEUTICS • Fukuda, Yuichi, eGC1 Preparer, Program Operations Specialist (E S 7), PHARMACEUTICS • Fukuda, Yuichi, Advance Preparer, Program Operations Specialist (E S 7), PHARMACEUTICS |
| A174393 | FA215628 | 62-7190 | 2021 | ADDUCTOMICS | Identification and quantification of drug-protein adducts by mass spectrometry | New | Research: Applied | Grant | 863006462 | ISOHERRANEN, NINA | 3080004000 | PHARMACEUTICS | SCHOOL OF PHARMACY | National Institutes of Health (NIH) | DHHS-National Institutes of Health (NIH) | Yes | National Institutes of Health (NIH) | $433,127 | 1R01GM147947-01 | Processed | 55.5 | 9/1/2022 | 6/30/2026 | 8/22/2022 | 2023 | A174393 | Professor | Unanticipated adverse drug reactions remain a major cause of post marketing withdrawals of drugs and of restricted access to new medications. Adverse drug reactions are often caused by reactive metabolites that form covalent adducts with proteins, but the identity and extent of protein adducts formed is often difficult to predict and characterize. Despite decades of research, current methods are unable to produce a comprehensive and quantitative catalog of xenobiotic protein adducts. This hinders progress in optimizing safety of novel medications and limits our ability to define mechanisms of clinically observed adverse drug reactions. To bridge this gap, we have developed innovative proteomic methods for discovery, characterization and quantification of protein adducts in simple and complex biological matrices. The goal of this proposal is to establish these methods for rapid, reliable and quantitative identification and characterization of drug-protein adducts, and uniquely customize these methods for human adductomics research impacting drug safety assessment. We will focus on covalent protein modifications resulting from metabolic oxidative activation of drugs. We will use a set of model compounds that are known to cause adverse events in patients and form reactive metabolites that likely result in protein adducts. In our aim 1 we will test the hypothesis that the modification masses and chemical characteristics of protein adducts formed by reactive metabolites in recombinant enzyme systems predict adduct formation in more complex systems such as liver microsomes and S9 fractions. Through this work we will optimize our proteomics methods for complex human liver preparations from individual donors. In aim 2 we will test the hypothesis that adduct formation varies quantitatively between individuals and due to differences in metabolic activity and individual genotype. In this aim we will establish quantitative adductomics for individual donors and define the basis for inter-individual variability in drug-protein adduct formation. In aim 3 we will test the hypothesis that human hepatocytes exposed to reactive metabolites generated in situ secrete proteins that have been adducted by the reactive intermediates. In this aim we will establish the in vitro relationship between hepatocyte adductomic burden and secretion of adducted proteins as biomarkers. When completed, the proposed studies will be transformative in integrating novel suite of cutting-edge tools and high-dimensional proteomics data to characterize the deep adductomic profiles of key drugs resulting in adverse drug reactions. The methods developed will enable the assessment and quantification of a broad range of adducts across the human proteome. The results will generate unprecedented insight into mechanisms of enzyme inactivation, liver adductomes formed after exposure to reactive metabolites and quantitative relationships between adduct formation and metabolic activity in the liver. The results may ultimately lead to novel drug discovery approaches that mitigate risk of adverse drug reactions resulting from adduct formation and to development of targeted therapeutic interventions designed to treat adverse drug reactions. | Isoherranen, Nina, Principal Investigator, Professor, PHARMACEUTICS • Zelter, Alexander, Co-Investigator, Research Scientist/Engineer-Senior (E S 10), BIOCHEMISTRY • Maccoss, Michael, Co-Investigator, Professor, GENOME SCIENCES • Camp, Alyssa L, Administrative Contact, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY • Kirkpatrick, Leila, Budget Contact, Grants And Contracts Manager/Specialist (E S 8), PHARMACEUTICS • Kirkpatrick, Leila, eGC1 Preparer, Grants And Contracts Manager/Specialist (E S 8), PHARMACEUTICS • Kirkpatrick, Leila, Budget Preparer, Grants And Contracts Manager/Specialist (E S 8), PHARMACEUTICS |
| A169720 | FA215468 | 62-7247 | 2021 | S10 ECLIPSE | ThermoFisher Scientific Orbitrap Eclipse with ETD and UVPD | Resubmission (Previously Denied) | Equipment | Grant | 855001420 | GUTTMAN, MIKLOS | 3080003000 | MEDICINAL CHEMISTRY | SCHOOL OF PHARMACY | National Institutes of Health (NIH) | DHHS-National Institutes of Health (NIH) | Yes | National Institutes of Health (NIH) | $1,184,239 | 1S10OD030237-01A1 | Processed | 0.0 | 9/1/2022 | 8/31/2023 | 8/29/2022 | 2023 | A169720 | Assistant Professor | Mass spectrometry has revolutionized bioanalytical tools to study key questions in biomedical sciences. The School of Pharmacy Mass Spectrometry Center has become a powerhouse in the use of structural mass spectrometry to gain new insights into drug-metabolizing enzymes, host-pathogen interactions, vaccine development strategies, and ways to modulate the immune system. Much of this work has given us new ways to track disease progression and identify novel therapeutics for a variety of diseases. This revised shared instrument proposal seeks to obtain a state-of-the-art mass spectrometer to overcome current limitations imposed by existing instruments and provide a much-needed tool for answering even more challenging and pressing questions in biomedical sciences. | Guttman, Miklos, Principal Investigator, Assistant Professor, MEDICINAL CHEMISTRY • Baker, David, Other, PROFESSOR, Biochemistry, BIOCHEMISTRY • Bhardwaj, Gaurav, Other, Assistant Professor, MEDICINAL CHEMISTRY • Atkins, William M., Other, Professor, MEDICINAL CHEMISTRY • Klevit, Rachel E, Other, Professor, BIOCHEMISTRY • Lee, Kelly K., Other, Associate Professor, MEDICINAL CHEMISTRY • Maly, Dustin James, Other, Professor, CHEMISTRY • Kollman, Justin M, Other, Associate Professor, BIOCHEMISTRY • Totah, Rheem A., Other, Associate Professor, MEDICINAL CHEMISTRY • Zheng, Ning, Other, Professor, PHARMACOLOGY • Whittington, Dale, Other, Teaching Associate, MEDICINAL CHEMISTRY • Kanov, Jeanine M., Administrative Contact, ADMINISTRATOR, Department of Medicinal Chemistry, MEDICINAL CHEMISTRY • Lidzbarski, Erik August Lee, Budget Contact, BUDGET/FISCAL ANALYST, MedChem - Admin, MEDICINAL CHEMISTRY • Kanov, Jeanine M., eGC1 Preparer, ADMINISTRATOR, Department of Medicinal Chemistry, MEDICINAL CHEMISTRY |
| A169938 | FA216449 | 62-7529 | 2021 | H2S | Circulating hydrogen sulfide, diabetes and diabetes-related cardiovascular disease | New | Research: Basic | Grant | 864002247 | TOTAH, RHEEM A. | 3080003000 | MEDICINAL CHEMISTRY | SCHOOL OF PHARMACY | National Institutes of Health (NIH) | DHHS-National Institutes of Health (NIH) | Yes | National Institutes of Health (NIH) | $673,106 | 1 R01 HL 163661-01 | Processed | 55.5 | 9/15/2022 | 8/31/2026 | 9/16/2022 | 2023 | A169938 | Associate Professor | Type 2 diabetes has reached epidemic proportions world-wide and carries a high burden of cardiovascular morbidity and mortality. Understanding potentially modifiable mechanisms that may influence the development of these multifactorial diseases has a substantial public health impact. This application seeks to identify modifiable factors, namely Hydrogen sulfide (H2S) and methylated hydrogen sulfide (MeSH), associated with risks of incident diabetes and diabetes-associated cardiovascular disease (CVD). Hydrogen sulfide (H2S) is one of three gasotransmitters, along with CO and NO, that are crucial for cell signaling and cell function. H2S acts as a vasodilator to improve cardiac function and protect against cardiac injury. Most pertinent to this proposal is the relevance of H2S to development of diabetes. Patients with type 2 diabetes showed a progressive reduction in the plasma H2S levels which was accompanied by poor glycemic control. More importantly, a reduction in the plasma H2S levels was found to be related to a history of cardiovascular disease in patients with type 2 diabetes. Compounds that release H2S and therefore increase systemic concentrations attenuated nephropathy in rats. The overall reduction in plasma H2S in diabetic patients may have implications in the pathophysiology of cardiovascular disease in diabetic patients. Guided by published animal studies and human data we hypothesize that higher plasma H2S levels are associated with lower risks of incident diabetes and diabetes-associated cardiovascular disease. To test this hypothesis, we will measure circulating H2S levels in humans, and in Aim 1, comprehensively examine H2S association with clinical outcomes, with a focus on type 2 diabetes. This is the largest examination of the association of H2S with health and disease in humans. Importantly, we supplement these observational associations with functional studies in Aim 2 that will experimentally investigate the molecular mechanism of H2S cardiac protection and discover the pathways regulating H2S biosynthesis and metabolism under stressors observed during diabetes. | Totah, Rheem A., Principal Investigator, Associate Professor, MEDICINAL CHEMISTRY • Zeigler, Maxwell Bertrand, Other, Research Scientist/Engineer 3 (E S 8), MEDICINAL CHEMISTRY • Carter, Ashley A, Other, Research Coordinator (E S 8), DEPARTMENT OF MEDICINE • Jensen, Paul N, Other, RESEARCH SCIENTIST/ENGINEER 4, Department of Medic, DEPARTMENT OF MEDICINE • Kannan, Nithya, Other, Research Consultant (E S 7), BIOSTATISTICS • McCrain, Cynthia, Other, MANAGER OF PROGRAM OPERATIONS, Department of Medic, DEPARTMENT OF MEDICINE • Enright, Erika A., Other, RESEARCH COORDINATOR, Biostatistics Dept: CHSCC Re, BIOSTATISTICS • Sitlani, Colleen M., Other, RESEARCH SCIENTIST/ENGINEER 4, Department of Medic, DEPARTMENT OF MEDICINE • Gharib, Sina A., Co-Investigator, Professor WOT, DEPARTMENT OF MEDICINE • Sotoodehnia, Nona, Co-Investigator, Associate Professor without Tenure, DEPARTMENT OF MEDICINE • Lemaitre, Rozenn N., Multiple PI, Research Associate Professor, DEPARTMENT OF MEDICINE • Kanov, Jeanine M., Administrative Contact, ADMINISTRATOR, Department of Medicinal Chemistry, MEDICINAL CHEMISTRY • Lidzbarski, Erik August Lee, Budget Contact, BUDGET/FISCAL ANALYST, MedChem - Admin, MEDICINAL CHEMISTRY • Kanov, Jeanine M., eGC1 Preparer, ADMINISTRATOR, Department of Medicinal Chemistry, MEDICINAL CHEMISTRY • Kanov, Jeanine M., Budget Preparer, ADMINISTRATOR, Department of Medicinal Chemistry, MEDICINAL CHEMISTRY |
| A161600 | FA214611 | 63-0171 | 2021 | R41 GUTTMAN | Multistage LC-MSn for automated glycan isomer assignment of glycopeptides | New | Research: Basic | Grant | 855001420 | GUTTMAN, MIKLOS | 3080003000 | MEDICINAL CHEMISTRY | SCHOOL OF PHARMACY | Protein Metrics | Private Industry | No | National Institutes of Health (NIH) | $135,685 | Processed | 55.5 | 4/1/2022 | 4/1/2022 | 8/17/2022 | 2023 | A161600 | Assistant Professor | A milieu of complex sugar structures cover of the cells of higher organisms and play critical roles in biology including regulation of host-pathogen interactions and modulating the immune system. Understanding the detailed structures of the sugars that are associated with disease onset can identify ways of preventing pathogens from infecting cells and provide better ways to detect and target cancer cells. The current proposal aims to implement our recent developments in sugar analysis through fragment ion ratio mapping into a software tool developed in partnership with Protein Metrics as part of a phase I NIH small business technology transfer grant. This technology will provide a much-needed tool for understand the role that structural sugars play regulation of the immune response, tumor progression, as well as to the biopharmaceutical community for characterization of the next generation of biotherapeutics | Guttman, Miklos, Principal Investigator, Assistant Professor, MEDICINAL CHEMISTRY • Mookherjee, Abhigya, Other, Postdoctoral Scholar, MEDICINAL CHEMISTRY • Kanov, Jeanine M., Administrative Contact, ADMINISTRATOR, Department of Medicinal Chemistry, MEDICINAL CHEMISTRY • Lidzbarski, Erik August Lee, Budget Contact, BUDGET/FISCAL ANALYST, MedChem - Admin, MEDICINAL CHEMISTRY • Kanov, Jeanine M., eGC1 Preparer, ADMINISTRATOR, Department of Medicinal Chemistry, MEDICINAL CHEMISTRY • Lidzbarski, Erik August Lee, Advance Preparer, BUDGET/FISCAL ANALYST, MedChem - Admin, MEDICINAL CHEMISTRY |
|
| A166645 | FA213504 | 63-3285 | 2021 | IMPLEMENTING VBF Y2 | Value-based Formulary-Essentials: Testing and Expanding on Value in Prescription Drug Benefit Design | Supplement and Extension | Research: Basic | Grant | 867004822 | SULLIVAN, SEAN | 3080001000 | DEPARTMENT OF PHARMACY | SCHOOL OF PHARMACY | Kaiser Permanente Washington Health Research Institute | Association & Non-Profits | No | Donaghue Foundation | $17,208 | RNG210194-BUDG01-UW-00 | Processed | 10.0 | 7/1/2020 | 12/31/2022 | 7/12/2022 | 2023 | A166645 | Professor | Dr. Sullivan will provide expertise in effective engagement and dissemination of study results to payersand purchasers, and will be available to meet 1-2 times per month to discuss study progress. | Sullivan, Sean, Principal Investigator, Professor, DEPARTMENT OF PHARMACY • Chen, Yilin, Other, Research Assistant (E S UAW ASE), DEPARTMENT OF PHARMACY • Kimura, Maya, Administrative Contact, ADMINISTRATOR, Department of Pharmacy, DEPARTMENT OF PHARMACY • Ahmed, Saveena, Budget Contact, Program Operations Analyst (E S 7), DEPARTMENT OF PHARMACY • Camp, Alyssa L, eGC1 Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY |
| A151543 | FA214427 | 63-8605 | 2021 | YEUNG-KELLY SBIR | Rat and Canine Microphysiological Systems of the Kidney Proximal Tubule for Chemical Toxicity Screening | New | Research: Basic | Grant | 878004403 | Yeung, Catherine | 3080001000 | DEPARTMENT OF PHARMACY | SCHOOL OF PHARMACY | Nortis, Inc | Private Industry | No | National Institute of Environmental Health and Science (NIEHS) | $218,689 | UW20200820-01 | Processed | 55.5 | 5/14/2022 | 4/30/2023 | 8/3/2022 | 2023 | A151543 | Assistant Professor | This project is a collaboration between Nortis Inc. (PI, T. Neumann) and the University of Washington School of Pharmacy (Co-Is, C. K. Yeung and E. J. Kelly). The goal of this application is to develop commercially viable kidney proximal tubule microphysiologic systems (KPT-MPS) using rat and canine proximal tubule epithelial cells (PTECs) that can be used in pre-clinical drug development to identify potential nephrotoxicity. | Yeung, Catherine, Principal Investigator, Assistant Professor, DEPARTMENT OF PHARMACY • Zelnick, Leila, Key Personnel, Research Assistant Professor, DEPARTMENT OF MEDICINE • Van Ness, Kirk Peter, Key Personnel, RESEARCH SCIENTIST/ENGINEER 2, PCEUT - KELLY LAB, PHARMACEUTICS • Himmelfarb, Jonathan, Key Personnel, Professor, DEPARTMENT OF MEDICINE • Bammler, Theodor K., Key Personnel, RESEARCH SCIENTIST/ENGINEER-SENIOR, Enviro & Occup, ENVIRO & OCCUP HEALTH • Kelly, Edward J, Multiple PI, Associate Professor, PHARMACEUTICS • Kimura, Maya, Administrative Contact, ADMINISTRATOR, Department of Pharmacy, DEPARTMENT OF PHARMACY • Ahmed, Saveena, Budget Contact, Program Operations Analyst (E S 7), DEPARTMENT OF PHARMACY • Camp, Alyssa L, eGC1 Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY • Camp, Alyssa L, Advance Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY |
| A180901 | FA219152 | 66-7964 | 2021 | NY DOH OG | Duplicative human B cell epitopes in Lyme Disease: B Cell Epitope Discovery and Mechanisms of Antibody Protection | New | Research: Basic | Contract | 855001420 | GUTTMAN, MIKLOS | 3080003000 | MEDICINAL CHEMISTRY | SCHOOL OF PHARMACY | Health Research, Inc. | Association & Non-Profits | No | National Institutes of Health (NIH) | $165,873 | 7221-01 | Returned by GCA | 55.5 | 9/16/22 | 9/15/23 | 11/29/22 | 2023 | A180901 | Assistant Professor | This subcontract is to aid in efforts for mapping epitopes of antibodies to various proteins on the surface of Borrelia burgdorferi involved in Lyme disease. Understanding how and where effective vs. ineffective antibodies bind to the surface proteins will be vital for developing effective therapeutics and vaccine strategies to combat Lyme disease. We will utilize our established Hydrogen/Deuterium exchange with mass spectrometry pipeline to analyze complexes of monoclonal antibodies provided through our collaboration and use this data to map the various epitopes. | Guttman, Miklos, Principal Investigator, Assistant Professor, MEDICINAL CHEMISTRY • Kanov, Jeanine M., Administrative Contact, ADMINISTRATOR, Department of Medicinal Chemistry, MEDICINAL CHEMISTRY • Lidzbarski, Erik August Lee, Budget Contact, BUDGET/FISCAL ANALYST, MedChem - Admin, MEDICINAL CHEMISTRY • Kanov, Jeanine M., eGC1 Preparer, ADMINISTRATOR, Department of Medicinal Chemistry, MEDICINAL CHEMISTRY |
| A180160 | FA212985 | 66-2506 | 2021 | MTAPSPHARMACOVIGILANCE | Pharmacovigilance system strengthening in MTaPS supported countries | New | Research: Applied | Grant | 874005710 | STERGACHIS, ANDREAS S | 3080001000 | DEPARTMENT OF PHARMACY | SCHOOL OF PHARMACY | Management Sciences for Health (MSH) | Association & Non-Profits | No | US Agency for International Development (USAID) | $83,745 | MTaPS-22-056 | Processed | 55.5 | 6/23/2022 | 12/30/2022 | 7/7/2022 | 2023 | A180160 | Professor | This project aims to ensure that the pharmacovigilance (PV) component of the regulatory systems strengthening work of MTaPS (Medicines Technologies and Pharmaceutical System) is promptly and effectively carried out to support improvements in health system performance in low- and middle-income countries, and that pharmacovigilance activities are fully implemented to ensure appropriate use of safe, effective, quality assured, and affordable essential medicines. | Stergachis, Andreas S, Principal Investigator, Professor, DEPARTMENT OF PHARMACY • Kimura, Maya, Administrative Contact, ADMINISTRATOR, Department of Pharmacy, DEPARTMENT OF PHARMACY • Ahmed, Saveena, Budget Contact, Program Operations Analyst (E S 7), DEPARTMENT OF PHARMACY • Camp, Alyssa L, eGC1 Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY |
| A164691 | FA219054 | 62-4639 | 2021 | K01 BARTHOLD | Long-term effects of today's medical care access policies on the future burden of Alzheimer's Disease and related dementias | Resubmission (Previously Denied) | Research: Basic | Grant | 821004379 | BARTHOLD, DOUGLAS G. | 3080001000 | DEPARTMENT OF PHARMACY | SCHOOL OF PHARMACY | National Institutes of Health (NIH) | DHHS-National Institutes of Health (NIH) | Yes | National Institutes of Health (NIH) | $122,040 | 5K01AG071843-02 | Processed | 8 | 2/1/22 | 11/30/26 | 12/6/22 | 2023 | A164691 | Research Assistant Professor | The management of cardiovascular and metabolic health, including type 2 diabetes mellitus (T2DM), is an important part of healthy aging and affects risk of Alzheimer’s disease and related dementias (ADRD). The proposed research aims to examine how the effects of today’s health insurance benefit design on management of T2DM can lead to long-term consequences on the incidence and burden of ADRD. This will be accomplished with an innovative simulation model, that connects existing models of T2DM progression and aging, to build understanding of the complicated interplay between health policies, healthy aging, and ADRD. | Barthold, Douglas G., Principal Investigator, Research Assistant Professor, DEPARTMENT OF PHARMACY • Grabowski, Thomas J, Other, Professor, RADIOLOGY • Basu, Anirban, Mentor, Professor, DEPARTMENT OF PHARMACY • Odegard, Peggy Soule, Mentor, Professor, DEPARTMENT OF PHARMACY • Liu, Shan, Mentor, Associate Professor, INDUSTRIAL&SYSTEMS ENG • Kimura, Maya, Administrative Contact, ADMINISTRATOR, Department of Pharmacy, DEPARTMENT OF PHARMACY • Ahmed, Saveena, Budget Contact, Program Operations Analyst (E S 7), DEPARTMENT OF PHARMACY • Camp, Alyssa L, eGC1 Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY • Camp, Alyssa L, Budget Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY |
| A180357 | FA213221 | 66-2746 | 2021 | SUPPLEMENT2TULANEGATES | Landscape analysis: Sentinel site readiness for Maternal Immunization Active Safety Surveillance in LMIC - Supplemental Project” | New | Research: Applied | Grant | 874005710 | STERGACHIS, ANDREAS S | 3080001000 | DEPARTMENT OF PHARMACY | SCHOOL OF PHARMACY | Tulane University | Private School, College, University | No | Bill and Melinda Gates Foundation | $26,587 | TUL-HSC-560197-21/22 | Processed | 10.0 | 4/1/2022 | 12/31/2022 | 7/12/2022 | 2023 | A180357 | Professor | In this supplemental activity, University of Washington will provide guidance and expert advice on assessing the readiness for active safety surveillance. | Stergachis, Andreas S, Principal Investigator, Professor, DEPARTMENT OF PHARMACY • ZARAA, SABRA, Other, Graduate Research Student Assistant (NE H UAW ASE), DEPARTMENT OF PHARMACY • Kimura, Maya, Administrative Contact, ADMINISTRATOR, Department of Pharmacy, DEPARTMENT OF PHARMACY • Ahmed, Saveena, Budget Contact, Program Operations Analyst (E S 7), DEPARTMENT OF PHARMACY • Camp, Alyssa L, eGC1 Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY • Camp, Alyssa L, Advance Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY |
| A171677 | FA217122 | 62-8045 | 2021 | NASA KIDNEY MPS | Extended culture of kidney MPS and organoids to model acute and chronic exposure to drugs and environmental toxins | New | Research: Basic | Contract | 878004403 | Yeung, Catherine | 3080001000 | DEPARTMENT OF PHARMACY | SCHOOL OF PHARMACY | National Aeronautics and Space Administration (NASA) | National Aeronautics and Space Administration | Yes | National Aeronautics and Space Administration (NASA) | $500,000 | 80ARC023CA001 | Processed | 55.5 | 11/14/22 | 11/14/23 | 11/15/22 | 2023 | A171677 | Assistant Professor | Kidney disease is a major public health problem that affects 850 million people worldwide and is the 9th leading cause of death. Finding disease cures and preventing disease progression demands immediate action and requires innovative strategies and models. Until recently, the lack of in vitro models that recapitulate kidney physiology, mimic the complexities of the nephron, model disease heterogeneity, and assess reparative mechanisms has hindered progress. Our team has approached the challenges of studying kidney disease by developing two innovative models: the proximal tubule kidney microphysiologic system (PTEC MPS) and the iPSC-derived kidney organoid (KO). Our single tubule PTEC MPS and dual-channel vascularized PTEC MPS have been used to evaluate acute nephrotoxicity of drugs, investigational compounds, and environmental toxins, and to predict human pharmacokinetics. In 2019 and 2021, 24 PTEC MPS units were sent to the International Space Station in semi-automated systems to evaluate the effects of microgravity on cell structure, resilience to toxic stimulus, vitamin D bioactivation (2019), and inflammatory/immunologic response to kidney stone precursors (2021). This system uses primary human cells, which allows for broad representation of males and females from diverse racial backgrounds. Our KOs, intricate 3-dimensional nephron-like structures, are differentiated from human iPSCs and exhibit at least 15 self-assembled cell types. KOs are amenable to CRISPR gene editing, which has been used to generate organoids with polycystic kidney disease phenotypes that form cysts similar to those observed in patients. In addition, we have developed high-throughput, automated, real-time systems for detecting cyst growth and nephrotoxicity phenotypes. Recently, we have used the organoid model to explore kidney injury associated with immunologically-induced glomerular disease and SARS-CoV2 infection.The goal of this project is to extend the longevity of our models to 6 months or more and develop semi-automated systems to test and maintain these systems. We believe that extending the longevity of our kidney models will allow for a better understanding of the development of chronic kidney diseases and the effects of chronic exposure to drugs, environmental toxins, pathogens, and other stressful stimuli. | Yeung, Catherine, Principal Investigator, Assistant Professor, DEPARTMENT OF PHARMACY • Wang, Lu, Other, RESEARCH SCIENTIST/ENGINEER 3, Enviro & Occup Heal, ENVIRO & OCCUP HEALTH • Calamia, Justina C., Other, RESEARCH SCIENTIST/ENGINEER 2, PCEUT- THUMMEL LAB, PHARMACEUTICS • BLACKBURN, SOPHIE, Other, Research Assistant (E S UAW ASE), DEPARTMENT OF MEDICINE • Himmelfarb, Jonathan, Co-Investigator, Professor, DEPARTMENT OF MEDICINE • Kelly, Edward J, Co-Investigator, Associate Professor, PHARMACEUTICS • Freedman, Benjamin S, Co-Investigator, Associate Professor WOT, DEPARTMENT OF MEDICINE • Thummel, Kenneth E., Co-Investigator, Professor, PHARMACEUTICS • Zelnick, Leila, Co-Investigator, Research Assistant Professor, DEPARTMENT OF MEDICINE • Bammler, Theodor K., Co-Investigator, RESEARCH SCIENTIST/ENGINEER-SENIOR, Enviro & Occup, ENVIRO & OCCUP HEALTH • Kimura, Maya, Administrative Contact, ADMINISTRATOR, Department of Pharmacy, DEPARTMENT OF PHARMACY • Ahmed, Saveena, Budget Contact, Program Operations Analyst (E S 7), DEPARTMENT OF PHARMACY • Camp, Alyssa L, eGC1 Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY • Camp, Alyssa L, Budget Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY • Camp, Alyssa L, Advance Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY |
| A177568 | FA212373 | 66-3500 | 2021 | VARIANT REINTERPRET | Development of recommendations and policies for genetic variant reclassification | New | Research: Basic | Grant | 867006453 | Veenstra, David | 3080001000 | DEPARTMENT OF PHARMACY | SCHOOL OF PHARMACY | Columbia University | Private School, College, University | No | National Institutes of Health (NIH) | $61,278 | 5(GG013080-01) | Processed | 55.5 | 7/1/2022 | 6/30/2023 | 8/18/2022 | 2023 | A177568 | Professor | In this supplemental activity, University of Washington will provide guidance and expert advice on assessing the readiness for active safety surveillance. | Stergachis, Andreas S, Principal Investigator, Professor, DEPARTMENT OF PHARMACY • ZARAA, SABRA, Other, Graduate Research Student Assistant (NE H UAW ASE), DEPARTMENT OF PHARMACY • Kimura, Maya, Administrative Contact, ADMINISTRATOR, Department of Pharmacy, DEPARTMENT OF PHARMACY • Ahmed, Saveena, Budget Contact, Program Operations Analyst (E S 7), DEPARTMENT OF PHARMACY • Camp, Alyssa L, eGC1 Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY • Camp, Alyssa L, Advance Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY |
| A184052 | FA218037 | 63-1641 | 2021 | GHDC PSP | GHDC Protein Sciences Platform | Supplement and Extension | Research: Basic | Grant | 856002915 | LEE, KELLY K. | 3080003000 | MEDICINAL CHEMISTRY | SCHOOL OF PHARMACY | Bill and Melinda Gates Foundation | Foundation | No | Bill and Melinda Gates Foundation | $607,567 | INV-010646 | Processed | 15 | 5/4/15 | 8/31/24 | 11/16/22 | 2023 | A184052 | Professor | We propose to collaborate with GH-VAP members in order to help advance infectious disease vaccine development towards a more rational, structure-based approach. The structural analysis methods we have developed through studies of the HIV Env (as a member of the BMGF CAVD) and influenza virus’ hemagglutinin glycoproteins are broadly applicable to a wide range of systems and are particularly powerful in providing structural information without the constraints of having to crystallize a protein. This opens the door to comparing protein and epitope structure in different constructs and from a range of variants with a goal of identifying how epitope structure changes in these different situations. The methods are also capable of examining antigen with flexible features such as loops and glycosylation intact, as well as in the presence of adjuvants or other components such as carrier molecules. An understanding of immunogen structures and their modes of recognition by antibodies provides a basis for iteratively altering the immunogen’s design in order to enhance the immune response.The primary biophysical and structural analytical methods we propose to use include hydrogen/deuterium-exchange mass spectrometry (HDX-MS), X-ray radical footprinting with mass spectrometry (XF-MS), small-angle X-ray scattering (SAXS), and electron microscopy (EM). These probe protein conformation and interactions with ligands such as receptors, antibodies and therapeutics. They also enable us to assess epitope stability and whether a protein is natively folded or misfolded. The approaches are amenable to a wide range of systems and sample conditions. In addition, quantitative biochemical and biophysical characterization of samples will be carried out in order to assess their compositional purity, conformational homogeneity, nativeness, and general physical properties such as stability, mass, monodispersity. Many of these techniques such as HDX-MS are frequently used by biotech and pharmaceutical companies to validate that biologic agents are properly folded as well as to assay for aggregation, degradation, and non-native structure.The specific analyses to be performed will depend on the particular collaboration, system of interest, and biological or translational question of interest. Some examples of questions include: 1) How does epitope presentation differ in different antigen constructs such as epitope scaffolds versus complete protein subunits or complexes, 2) How does antigen structure change in the presence of adjuvants, 3) What degree of conformational heterogeneity is observed in a sample, 4) How are antigens organized, distributed, and oriented on more complex vectors such as VSV, HBsAg, liposomes, and VLPs, 5) How do specific modifications to an antigen alter its structure, epitope presentation and stability?SARS-Cov-2: Given the global crisis relating to the SARS-CoV-2/COVID19 pandemic, we will prioritize analysis of antigens under development as well as analysis of the SARS-CoV-2 interactions with neutralizing antibodies and receptors. These projects will examine antigen structure, assess compositional and conformational heterogeneity of sample preparations, measure antigen stability, determine glycan composition, and characterize the antibody and receptor binding profiles of antigens. | Lee, Kelly K., Principal Investigator, Professor, MEDICINAL CHEMISTRY • Kanov, Jeanine M., Administrative Contact, ADMINISTRATOR, Department of Medicinal Chemistry, MEDICINAL CHEMISTRY • Lidzbarski, Erik August Lee, Budget Contact, BUDGET/FISCAL ANALYST, MedChem - Admin, MEDICINAL CHEMISTRY • Lidzbarski, Erik August Lee, eGC1 Preparer, BUDGET/FISCAL ANALYST, MedChem - Admin, MEDICINAL CHEMISTRY |
| A174572 | FA205130 | 80-1045 | 2021 | ALLERGFELL25 BALDWIN | Allergan Fellowship Program in Pharmacoeconomics (Baldwin) | New | Fellowship: Research Graduate/Professional | Grant | 866006427 | DEVINE, EMILY E. | 3080001000 | DEPARTMENT OF PHARMACY | SCHOOL OF PHARMACY | AbbVie Inc. | Private Industry | No | AbbVie Inc. | $239,243 | Fellowship #25 | Processed | 9.0 | 7/1/2022 | 6/30/2024 | 7/21/2022 | 2023 | A174572 | Professor | The University of Washington will utilize a previously developed model (RISE) evaluating the cost-utility of population screening for three CDC Tier-1 genomic applications (HBOC, FH, and Lynch) to assess the cost-utility of variant reinterpretation. The focus of the analysis will be reinterpretation of VUSs in HBOC vs. no variant reinterpretation. Scenario analyses will be conducted assessing different reinterpretation costs and frequencies. Assessment of FH and Lynch reinterpretation will be incorporated as feasible.The investigators will lead the development of a manuscript describing the analysis, results, and interpretation, in collaboration with investigators at Columbia and participating members of the RISE modeling consortium. | Veenstra, David, Principal Investigator, Professor, DEPARTMENT OF PHARMACY • Guzauskas, Greg, Other, Research Scientist/Engineer 4 (E S 9), DEPARTMENT OF PHARMACY • Kimura, Maya, Administrative Contact, ADMINISTRATOR, Department of Pharmacy, DEPARTMENT OF PHARMACY • Camp, Alyssa L, Budget Contact, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY • Hayes, Lori T, eGC1 Preparer, Program Operations Specialist (E S 8), REHABILITATION MEDICIN • Hayes, Lori T, Budget Preparer, Program Operations Specialist (E S 8), REHABILITATION MEDICIN • Camp, Alyssa L, Advance Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY |
| A179616 | FA218423 | 66-2278 | 2021 | PROJECT 3 ON CAMPUS | Adult Changes in Thought (ACT) Research Program (Pharmacoepidemiology Project 3 on-campus)) | Non-Competing Revision | Research: Applied | Cooperative Agreement | 878005497 | Gray, Shelly L. | 3080001000 | DEPARTMENT OF PHARMACY | SCHOOL OF PHARMACY | Kaiser Permanente Washington Health Research Institute | Association & Non-Profits | No | National Institute on Aging (NIA) | $121,704 | RNG211394-UW-OnC | Processed | 55.5 | 5/1/22 | 4/30/23 | 11/22/22 | 2023 | A179616 | Professor | Project 3 (P3) takes a multifaceted approach to examine links between common drugs and brain health by using an array of brain-related measures in the Adult Changes in Thought (ACT) cohort to deepen our understanding about these relationships and mechanisms. Medications are an important exposure in the life course epidemiology framework that ties the ACT U19 Program together. Medications for chronic conditions are taken over several years, often beginning in mid-life, and chronic regimens achieve consistent blood levels, so toxic or protective brain effects of medication exposures are plausible. P3 will address important gaps in the literature using innovative methods that will inform medical decision-making for drug selection and address a key limitation to dementia pharmacoepidemiology by looking for mechanisms underlying medication-dementia links. The ACT U19 Program is uniquely positioned for both epidemiologic and cellular mechanistic research to examine relative benefits and risks of medications, all within a longitudinal, population-based setting that is not possible with other dementia cohort studies. | Gray, Shelly L., Principal Investigator, Professor, DEPARTMENT OF PHARMACY • Barthold, Douglas G., Co-Investigator, Research Assistant Professor, DEPARTMENT OF PHARMACY • Marcum, Zachary, Co-Investigator, Associate Professor, DEPARTMENT OF PHARMACY • Crane, Paul K, Multiple PI, Professor without Tenure, DEPARTMENT OF MEDICINE • Camp, Alyssa L, Administrative Contact, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY • Black, Kari Lynn Swanson, Budget Contact, MANAGER OF PROGRAM OPERATIONS, Department of Medic, DEPARTMENT OF MEDICINE • Chin, David G., eGC1 Preparer, BUDGET/FISCAL ANALYST LEAD, Department of Medicine, DEPARTMENT OF MEDICINE • Camp, Alyssa L, Advance Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY |
| A174644 | FA205140 | 80-1046 | 2021 | ALLERGFELL26 KIM | Allergan Fellowship Program in Pharmacoeconomics (Kim) | New | Fellowship: Research Graduate/Professional | Grant | 866006427 | DEVINE, EMILY E. | 3080001000 | DEPARTMENT OF PHARMACY | SCHOOL OF PHARMACY | AbbVie Inc. | Private Industry | No | AbbVie Inc. | $239,243 | Fellowship #26 | Processed | 9.0 | 7/1/2022 | 6/30/2024 | 7/21/2022 | 2023 | A174644 | Professor | Graduate Fellowship In Pharmacoeconomics in Health Systems/Managed Care Master of Science (M.S.) In Pharmaceutical SciencesArea of emphasis: Pharmaceutical Economics and Outcomes Research | Devine, Emily E., Principal Investigator, Professor, DEPARTMENT OF PHARMACY • Kimura, Maya, Administrative Contact, ADMINISTRATOR, Department of Pharmacy, DEPARTMENT OF PHARMACY • Ahmed, Saveena, Budget Contact, Program Operations Analyst (E S 7), DEPARTMENT OF PHARMACY • Hayes, Lori T, eGC1 Preparer, Program Operations Specialist (E S 8), REHABILITATION MEDICINE |
| A180160 | FA218803 | 66-2506 | 2021 | MTAPSPHARMACOVIGILANCE | Pharmacovigilance system strengthening in MTaPS supported countries | New | Research: Applied | Grant | 874005710 | STERGACHIS, ANDREAS S | 3080001000 | DEPARTMENT OF PHARMACY | SCHOOL OF PHARMACY | Management Sciences for Health (MSH) | Association & Non-Profits | No | US Agency for International Development (USAID) | $5,720 | MTaPS-22-056 (PO# 22MSH0480), | Processed | 55.5 | 6/23/22 | 12/30/22 | 11/16/22 | 2023 | A180160 | Professor | This project aims to ensure that the pharmacovigilance (PV) component of the regulatory systems strengthening work of MTaPS (Medicines Technologies and Pharmaceutical System) is promptly and effectively carried out to support improvements in health system performance in low- and middle-income countries, and that pharmacovigilance activities are fully implemented to ensure appropriate use of safe, effective, quality assured, and affordable essential medicines. | Stergachis, Andreas S, Principal Investigator, Professor, DEPARTMENT OF PHARMACY • Kimura, Maya, Administrative Contact, ADMINISTRATOR, Department of Pharmacy, DEPARTMENT OF PHARMACY • Ahmed, Saveena, Budget Contact, Program Operations Analyst (E S 7), DEPARTMENT OF PHARMACY • Camp, Alyssa L, eGC1 Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY |
| A149959 | FA219176 | 66-5602 | 2021 | THUMMEL_WSU U54 RENWAL | Natural Product-Drug Interaction Research: The Roadmap to Best Practices | Competing Renewal | Research: Basic | Cooperative Agreement | 868006623 | THUMMEL, KENNETH E. | 3080004000 | PHARMACEUTICS | SCHOOL OF PHARMACY | Washington State University (WSU) | Washington School, College, University | No | National Center for Complementary and Integrative Health (NCCIH) | $395,340 | 132416-SPC004779 | Processed | 55.5 | 9/1/22 | 8/31/23 | 12/5/22 | 2023 | A149959 | Professor | Administrative Core The Administrative Core under the parent grant has a two-fold responsibility. At the program level, the Administrative Core coordinates the basic administrative and financial services to the Cores and participating institutions. At the project level, the Administrative Core is charged with 1) identifying a priority list of NPs that will be investigated for drug interaction liabilities, 2) designing appropriate in vitro and clinical interaction studies involving the selected NPs, 3) supporting the interaction projects by sourcing and ensuring quality of the NP study materials and by coordinating analysis of the pharmacokinetic samples generated from the interaction projects, and 4) disseminating the data generated from the interaction projects via a robust data repository and public-facing portal.The Administrative Core component of this subcontract supports the effort of Dr. Kenneth Thummel (Co-I). Dr. As a member of the Administrative Core and Steering Committee, Dr. Thummel will provide advice and counsel for all elements of the programmatic function of the Administrative Core, including execution of the Interaction Projects, development of new recommended approaches (RAs) and the dissemination of NaPDI research findings and evaluation of its impact on the research community.Pharmacology Core For the 5-year period of the parent grant, the Pharmacology Core has the principal responsibility of designing and implementing the Interaction Projects. The process begins with the selection of natural products (NPs) for investigation by the NaPDI team. This occurs in concert with input from the Steering Committee (representing leadership of all Cores and the NCCIH grant program officer). The list of NPs proposed in this grant application (kratom, hemp, goldenseal/echinacea, and black pepper) is the result of such interactions. The NP priority list will be updated regularly throughout the course of the grant, as described in our Research Strategy. NP selection is the product of an extensive literature review and, for kratom and hemp, carefully orchestrated preclinical studies that led to a definitive assessment of their risk or safety and the need for further investigation. Additional pre-clinical interaction studies of selected NPs will be performed by the Pharmacology Core team, as needed. Results will be evaluated using rigorous, predefined decision trees as guides, for determination of the need for a clinical NP-drug interaction study, and implemented, as described in the Research Strategy.The Pharmacology Core component of this UW subcontract supports the efforts of Dr. Allan Rettie (Co-I) and Dr. Jashvant Unadkat (Co-I), two preeminent translational pharmacologists, and their lab personnel. The two Co-I will work with the Pl of the parent grant, Dr. Mary Paine, in reassessing current priority natural products: kratom, hemp, combined goldenseal/echinacea and black pepper, and in periodically evaluating new, emerging NPs for prioritization. The UW portion of the Pharmacology Core will conduct all the necessary preclinical studies for identifying potential drug interactions with hemp and the combined goldenseal/echinacea product and associated constituents. At present, the preclinical studies will largely consist of validated in vitro screening assays for known drug metabolizing enzymes; possible interactions with drug transporters will be sub-contracted to Solvo. Bench support will be provided by a qualified postdoctoral fellow in Dr. Unadkat’s lab, Dr. Sumit Bansal, and a senior staff scientist in Dr. Rettie’s lab, Dr. Matt McDonald. Dr. Unadkat will also oversee the development of PBPK models for cannabidiol (from hemp) and goldenseal/echinacea – probe drug interactions.Analytical Core Under the parent grant, the Analytical Core is charged with 1) characterizing the bioactive constituents of the priority natural products selected for the Interaction Projects, 2) isolating and supplying the bioactive extracts of selected natural products for preclinical studies on drug interaction potentials, and 3) supporting the analysis of samples generated from the clinical human subject studies under the Interaction Projects. The Analytical Core component of this UW subcontract will focus on the third charge, mainly to provide the critical analytical support for the clinical studies on standardized hemp and goldenseal/echinacea extracts in regards to their potential for modulating drug metabolizing enzymes and drug transporters. The analysis tasks will consist of development of sensitive and specific mass-spectrometry based assays for the drug and/or metabolites of the drug probes used in the enzyme or transporter screens and key constituents present in the natural product extracts (i.e., the perpetrators). All assays will be performed in our shared research resource PK Lab in the Department of Pharmaceutics. A secondary assignment for the UW component of the Analytical Core is to provide back-up support or overflow capacity in the analysis of biological samples (i.e., blood/plasma and urine) collected from human subject studies of kratom and black pepper, under the Interaction Projects. As currently proposed, these analyses are to be handled by Dr. Mary Paine's laboratory at WSU. UW PK Lab will provide back-up LC-MS/MS support on those occasions when the WSU LC-MS facility develops major instrumentation problems. The PK Lab will also handle overflow samples generated from pre-clinical studies by investigators in the Pharmacology Core (i.e, labs of Drs. Unadkat and Rettie). | Thummel, Kenneth E., Principal Investigator, Professor, PHARMACEUTICS • Brauchla, Calder C, Other, Research Scientist/Engineer 1 (E S 6), PHARMACEUTICS • Bansal, Sumit, Other, Postdoctoral Scholar (E S UAW Postdoc), PHARMACEUTICS • McDonald, Matthew G., Other, RESEARCH SCIENTIST/ENGINEER 3, MedChem - Rettie La, MEDICINAL CHEMISTRY • Unadkat, Jashvant D, Co-Investigator, Professor, PHARMACEUTICS • Rettie, Allan E., Co-Investigator, Professor, MEDICINAL CHEMISTRY • Kimura, Maya, Administrative Contact, ADMINISTRATOR, Department of Pharmacy, DEPARTMENT OF PHARMACY • Kirkpatrick, Leila, Budget Contact, Grants And Contracts Manager/Specialist (E S 8), PHARMACEUTICS • Camp, Alyssa L, eGC1 Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY • Camp, Alyssa L, Advance Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY • Deprey, Teresa M, Advance Preparer, Administrator (E S 11), DEPARTMENT OF MEDICINE • Olanrewaju, Malik F., Advance Preparer, Assistant To The Dean (E S 8), PHARMACY-DEAN'S OFFICE |
| A180071 | FA216389 | 66-6688 | 2021 | NY DOH | Duplicative human B cell epitopes in Lyme Disease: B Cell Epitope Discovery and Mechanisms of Antibody Protection | New | Research: Basic | Contract | 855001420 | GUTTMAN, MIKLOS | 3080003000 | MEDICINAL CHEMISTRY | SCHOOL OF PHARMACY | Health Research, Inc. | Association & Non-Profits | No | National Institutes of Health (NIH) | $60,000 | 7212-01 | Processed | 55.5 | 8/1/22 | 7/31/23 | 10/4/22 | 2023 | A180071 | Assistant Professor | This subcontract is to aid in efforts for mapping epitopes of antibodies to various proteins on the surface of Borrelia burgdorferi involved in Lyme disease. Understanding how and where effective vs. ineffective antibodies bind to the surface proteins will be vital for developing effective therapeutics and vaccine strategies to combat Lyme disease. We will utilize our established Hydrogen/Deuterium exchange with mass spectrometry pipeline to analyze complexes of monoclonal antibodies provided through our collaboration and use this data to map the various epitopes. | Guttman, Miklos, Principal Investigator, Assistant Professor, MEDICINAL CHEMISTRY • Kanov, Jeanine M., Administrative Contact, ADMINISTRATOR, Department of Medicinal Chemistry, MEDICINAL CHEMISTRY • Lidzbarski, Erik August Lee, Budget Contact, BUDGET/FISCAL ANALYST, MedChem - Admin, MEDICINAL CHEMISTRY • Kanov, Jeanine M., eGC1 Preparer, ADMINISTRATOR, Department of Medicinal Chemistry, MEDICINAL CHEMISTRY • Kanov, Jeanine M., Budget Preparer, ADMINISTRATOR, Department of Medicinal Chemistry, MEDICINAL CHEMISTRY |
| A183925 | FA217630 | 66-6817 | 2021 | SCRI STAFF ASSIGNMENT | SCRI Staff Assignment | New | IPA/JPA/Staff Assignment | Grant | 867006435 | HO, RODNEY | 3080004000 | PHARMACEUTICS | SCHOOL OF PHARMACY | Seattle Children's Research Institute (SCRI) | Association & Non-Profits | No | Seattle Children's Research Institute (SCRI) | $5,025 | N/A | Processed | 4 | 7/1/21 | 6/30/23 | 10/7/22 | 2023 | A183925 | Professor | This agreement between the Seattle Children’s Research Institute (SCRI) and the University of Washington (UW),governs the transfer between the parties of salary expenses for the following named individual, as set forth in the Agreement Regarding Joint Research Projects between SCRI and UW, as signed and as subsequently amended. The terms and conditions of the Agreement govern this Staff Assignment Agreement.- Meehan, Anna (Research Assistant, Seattle Children's Research Institute)The employee named above is hereby assigned by his/her employer to perform unspecified work at and for the Work Site Organization. | Ho, Rodney J.Y., Principal Investigator, Professor, PHARMACEUTICS • Bly, Randall, Other, Associate Professor without Tenure, OTOLARYNG-HD&NECK SURG • Josleyn, Alyshia R, Administrative Contact, Administrator (E S 10), PHARMACEUTICS • Fukuda, Yuichi, Budget Contact, Program Operations Specialist (E S 7), PHARMACEUTICS • Fukuda, Yuichi, eGC1 Preparer, Program Operations Specialist (E S 7), PHARMACEUTICS |
| A181472 | FA216766 | 66-7149 | 2021 | HHMI EPI | Targeting essential surface-accessible processes of bacterial gut pathogens with designed peptides | New | Research: Basic | Grant | 849003865 | BHARDWAJ, GAURAV | 3080003000 | MEDICINAL CHEMISTRY | SCHOOL OF PHARMACY | Howard Hughes Medical Institute (HHMI) | Association & Non-Profits | No | Howard Hughes Medical Institute (HHMI) | $1,051,454 | Processed | 20 | 1/1/23 | 12/31/26 | 10/14/22 | 2023 | A181472 | Professor | Graduate Fellowship In Pharmacoeconomics in Health Systems/Managed Care Master of Science (M.S.) In Pharmaceutical SciencesArea of emphasis: Pharmaceutical Economics and Outcomes Research | Bhardwaj, Gaurav, Principal Investigator, Assistant Professor, MEDICINAL CHEMISTRY • Kanov, Jeanine M., Administrative Contact, ADMINISTRATOR, Department of Medicinal Chemistry, MEDICINAL CHEMISTRY • Lidzbarski, Erik August Lee, Budget Contact, BUDGET/FISCAL ANALYST, MedChem - Admin, MEDICINAL CHEMISTRY • Kanov, Jeanine M., eGC1 Preparer, ADMINISTRATOR, Department of Medicinal Chemistry, MEDICINAL CHEMISTRY |
|
| A186843 | FA220227 | 66-8543 | 2021 | C-19 USP PY4 TO3 | OHS Cross Bureau COVID-19 PY4 Workplan | New | Research: Applied | Cooperative Agreement | 874005710 | STERGACHIS, ANDREAS S | 3080001000 | DEPARTMENT OF PHARMACY | SCHOOL OF PHARMACY | U.S. Pharmacopeial Convention (USP) | Association & Non-Profits | No | US Agency for International Development (USAID) | $74,931 | 1000264-MKTA.DOCD | Processed | 55.5 | 1/1/23 | 6/30/23 | 12/29/22 | 2023 | A186843 | Professor | Advanced regulatory authorities have defined pathways for making new promising treatments available to their populations before complete data is available for granting full regulatory approvals particularly in cases of emergency. For COVID-19, many NMRAs have used the emergency use authorization (EUA) pathway. The United States Food and Drug Administration (FDA) defines an EUA as a mechanism to facilitate the availability and use of medical countermeasures during public health emergencies, such as the current COVID-19 pandemic. Guidance documents are available through regulatory authorities such as the FDA, European Medicines Agency (EMA), World Health Organization (WHO), and others to support low- and middle-income countries (LMICs) to adopt EUA procedures for COVID-19 related medical products to make the needed medical products available for their populations. Many NMRAs have adopted and relied on their reference regulatory agencies’ review process and decision to grant EUA for various types of COVID-19 vaccines, medicines, and supplies. In LIMCs, however, NMRAs have struggled to do so, due in part to a lack of regulatory and technical know-how to adopt and use the EUA process in their local settings so they can build a sustainable EUA pathway for the COVID-19 pandemic as well as future infectious outbreaks. QM+ will engage University of Washington to undertake this activity and will collaborate closely Centre for Innovation in Regulatory Science (CIRS), and WHO as necessary. The planned tasks for this activity include conducting a document review of existing EUA guidelines by WHO, FDA, EMA, and other mature regulatory agencies; conducting a rapid assessment of country emergency regulatory processes and procedures for lifesaving medicines in emergency situations, targeting up to 17 PQM+ countries; developing a proposed model EUA guidance with a checklist for LMICs; and disseminating the proposed model EUA guidance, including information to be made available on NMRA websites for health care providers and other concerned parties. The purpose of the technical engagement of the UW is to develop a practical guidance document with an accompanying checklist that the NMRAs in LMICs can adopt and use in their respective settings for timely authorization for emergency use of COVID-19 therapeutics. The primary audience of the guide will be regulatory authorities in LMICs that seek to expedite market authorization decisions, including through EUA, and fast-track approval processes for emergency products. The goal is to facilitate rapid access to safe, effective, and quality medicinal products while also helping to improve NMRA’s communication and transparency with the public to maintain trust in the rigor of the regulatory review process and confidence in the safety, effectiveness, and quality of approved products. After the COVID-19 pandemic, the guide can be used as a regulatory tool to prepare for future public health emergencies as part of a country’s contingency plan to ensure access to quality, safe and effective medicinal products during emergencies. | Stergachis, Andreas S, Principal Investigator, Professor, DEPARTMENT OF PHARMACY • Lane, Jeffrey Patrick, Key Personnel, Clinical Assistant Professor - Salaried, GLOBAL HEALTH • Kimura, Maya, Administrative Contact, ADMINISTRATOR, Department of Pharmacy, DEPARTMENT OF PHARMACY • Ahmed, Saveena, Budget Contact, Program Operations Analyst (E S 7), DEPARTMENT OF PHARMACY • Camp, Alyssa L, eGC1 Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY |
| A169172 | FA217355 | 80-0735 | 2019 | ALLERGFELL24 DOMINGUEZ | Allergan Fellowship Program in Pharmacoeconomics (Dominguez) | New | Fellowship: Research Graduate/Professional | Grant | 866006427 | DEVINE, EMILY E. | 3080001000 | DEPARTMENT OF PHARMACY | SCHOOL OF PHARMACY | Allergan, Inc. | Private Industry | No | Allergan, Inc. | $4,678 | Fellowship #24 | Processed | 9 | 7/1/21 | 6/30/23 | 10/4/22 | 2023 | A169172 | Professor | Graduate Fellowship In Pharmacoeconomics in Health Systems/Managed Care Master of Science (M.S.) In Pharmaceutical SciencesArea of emphasis: Pharmaceutical Economics and Outcomes Research | Devine, Emily E., Principal Investigator, Professor, DEPARTMENT OF PHARMACY • Dominguez, Annaliza, Other, , • Carlson, Joshua J., Mentor, Associate Professor, DEPARTMENT OF PHARMACY • Kimura, Maya, Administrative Contact, ADMINISTRATOR, Department of Pharmacy, DEPARTMENT OF PHARMACY • Ahmed, Saveena, Budget Contact, Program Operations Analyst (E S 7), DEPARTMENT OF PHARMACY • Camp, Alyssa L, eGC1 Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY |
| A169166 | FA217353 | 80-0745 | 2019 | ALLERGFELL 23 AHMADYAR | Allergan Fellowship Program in Pharmacoeconomics (Ahmadyar) | New | Fellowship: Research Graduate/Professional | Grant | 866006427 | DEVINE, EMILY E. | 3080001000 | DEPARTMENT OF PHARMACY | SCHOOL OF PHARMACY | Allergan, Inc. | Private Industry | No | Allergan, Inc. | $5,490 | Fellowship #23 | Processed | 9 | 7/1/21 | 6/30/23 | 10/4/22 | 2023 | A169166 | Professor | Graduate Fellowship In Pharmacoeconomics in Health Systems/Managed Care Master of Science (M.S.) In Pharmaceutical SciencesArea of emphasis: Pharmaceutical Economics and Outcomes Research | Devine, Emily E., Principal Investigator, Professor, DEPARTMENT OF PHARMACY • AHMADYAR, GINA, Other, Postdoctoral Scholar - Fellow (UAW Postdoc), DEPARTMENT OF PHARMACY • Hansen, Ryan, Mentor, Associate Professor, DEPARTMENT OF PHARMACY • Kimura, Maya, Administrative Contact, ADMINISTRATOR, Department of Pharmacy, DEPARTMENT OF PHARMACY • Ahmed, Saveena, Budget Contact, Program Operations Analyst (E S 7), DEPARTMENT OF PHARMACY • Camp, Alyssa L, eGC1 Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY |
| A174575 | FA217479 | 80-0851 | 2021 | SEAGEN FELLOWSHIP | Seagen Fellowship Program | New | Fellowship: Research Graduate/Professional | Grant | 863005316 | CARLSON, JOSHUA J. | 3080001000 | DEPARTMENT OF PHARMACY | SCHOOL OF PHARMACY | Seagen, Inc. | Private Industry | No | Seagen, Inc. | $285,105 | Processed | 9 | 10/13/22 | 6/30/25 | 11/10/22 | 2023 | A174575 | Associate Professor | Seagen will support a two-year fellowship program in Health Economics and Outcomes Research (HEOR) through the University and its Department of Pharmacy. | Carlson, Joshua J., Principal Investigator, Associate Professor, DEPARTMENT OF PHARMACY • Basu, Anirban, Other, Professor, DEPARTMENT OF PHARMACY • Sullivan, Sean, Other, Professor, DEPARTMENT OF PHARMACY • Veenstra, David, Other, Professor, DEPARTMENT OF PHARMACY • Devine, Emily E., Other, Professor, DEPARTMENT OF PHARMACY • Hansen, Ryan, Other, Associate Professor, DEPARTMENT OF PHARMACY • Bansal, Aasthaa, Other, Associate Professor, DEPARTMENT OF PHARMACY • Barthold, Douglas G., Other, Research Assistant Professor, DEPARTMENT OF PHARMACY • Marcum, Zachary, Other, Associate Professor, DEPARTMENT OF PHARMACY • Bacci, Jennifer Lynn, Other, Associate Professor, DEPARTMENT OF PHARMACY • Ramsey, Scott D., Other, Professor without Tenure, DEPARTMENT OF MEDICINE • Kimura, Maya, Administrative Contact, ADMINISTRATOR, Department of Pharmacy, DEPARTMENT OF PHARMACY • Ahmed, Saveena, Budget Contact, Program Operations Analyst (E S 7), DEPARTMENT OF PHARMACY • Camp, Alyssa L, eGC1 Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY • Camp, Alyssa L, Advance Preparer, Grants And Contracts Manager/Specialist (E S 9), DEPARTMENT OF PHARMACY |
|
| A174572 | FA218838 | 80-1045 | 2021 | ALLERGFELL25 BALDWIN | Allergan Fellowship Program in Pharmacoeconomics (Baldwin) | New | Fellowship: Research Graduate/Professional | Grant | 866006427 | DEVINE, EMILY E. | 3080001000 | DEPARTMENT OF PHARMACY | SCHOOL OF PHARMACY | AbbVie Inc. | Private Industry | No | AbbVie Inc. | $9,267 | 220158.1 | Processed | 9 | 7/1/22 | 6/30/24 | 11/22/22 | 2023 | A174572 | Professor | Graduate Fellowship In Pharmacoeconomics in Health Systems/Managed Care Master of Science (M.S.) In Pharmaceutical SciencesArea of emphasis: Pharmaceutical Economics and Outcomes Research | Devine, Emily E., Principal Investigator, Professor, DEPARTMENT OF PHARMACY • Kimura, Maya, Administrative Contact, ADMINISTRATOR, Department of Pharmacy, DEPARTMENT OF PHARMACY • Ahmed, Saveena, Budget Contact, Program Operations Analyst (E S 7), DEPARTMENT OF PHARMACY • Hayes, Lori T, eGC1 Preparer, Program Operations Specialist (E S 8), REHABILITATION MEDICINE |
| A174644 | FA218837 | 80-1046 | 2021 | ALLERGFELL26 KIM | Allergan Fellowship Program in Pharmacoeconomics (Kim) | New | Fellowship: Research Graduate/Professional | Grant | 866006427 | DEVINE, EMILY E. | 3080001000 | DEPARTMENT OF PHARMACY | SCHOOL OF PHARMACY | AbbVie Inc. | Private Industry | No | AbbVie Inc. | $9,267 | 220159.1 | Processed | 9 | 7/1/22 | 6/30/24 | 11/29/22 | 2023 | A174644 | Professor | Graduate Fellowship In Pharmacoeconomics in Health Systems/Managed Care Master of Science (M.S.) In Pharmaceutical SciencesArea of emphasis: Pharmaceutical Economics and Outcomes Research | Devine, Emily E., Principal Investigator, Professor, DEPARTMENT OF PHARMACY • Kimura, Maya, Administrative Contact, ADMINISTRATOR, Department of Pharmacy, DEPARTMENT OF PHARMACY • Ahmed, Saveena, Budget Contact, Program Operations Analyst (E S 7), DEPARTMENT OF PHARMACY • Hayes, Lori T, eGC1 Preparer, Program Operations Specialist (E S 8), REHABILITATION MEDICINE |